

CURRICULUM VITAE

A. Michael Lincoff, M.D.

OFFICE ADDRESS:

Department of Cardiovascular Medicine
Desk F25
The Cleveland Clinic Foundation
9500 Euclid Avenue
Cleveland, Ohio 44195
(216) 444-2367 (Office)
(216) 444-2200, Page Number 23189 (Page Operator)
FAX (216) 444-8050
Email: lincofa@ccf.org

ACADEMIC APPOINTMENTS:

2004 - present Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western
Reserve University

1998 - 2004 Associate Professor of Medicine
Cleveland Clinic Health Sciences Center of the Ohio State
University School of Medicine

1994 - 1998 Assistant Professor of Medicine
Cleveland Clinic Health Sciences Center of the Ohio State
University School of Medicine

MEDICAL CENTER APPOINTMENTS:

1994-present Staff, Interventional Cardiology
Department of Cardiovascular Medicine
The Cleveland Clinic Foundation

1994-present Staff
Joseph J. Jacobs Center for Thrombosis and Vascular Biology
Department of Molecular Cardiology
The Cleveland Clinic Research Institute

1993 - 1994 Associate Staff, Interventional Cardiology
Department of Cardiology
The Cleveland Clinic Foundation

1993 - 1994

Associate Staff
Center for Thrombosis and Vascular Biology
Department of Molecular Cardiology
The Cleveland Clinic Research Institute

1993 - 2001

Director, Experimental Interventional Laboratory
Departments of Cardiology and Molecular Cardiology
The Cleveland Clinic Foundation and Research Institute

EDUCATION:

Undergraduate:

Carnegie-Mellon University 1978-1982
Pittsburgh, Pennsylvania
B.S. Chemical/Biomedical Engineering with
University Honors

Medical School:

Johns Hopkins University School of Medicine
1982-1986
Baltimore, Maryland
M.D.

POSTDOCTORAL TRAINING:

Internship:

Intern in Internal Medicine
Beth Israel Hospital, Harvard Medical School
Boston, Massachusetts 1986-1987

Residency:

Resident in Internal Medicine
Beth Israel Hospital, Harvard Medical School
Boston, Massachusetts 1987-1989

Fellowships:

Fellow in Cardiovascular Medicine
University of Michigan Medical Center
Ann Arbor, Michigan 1989-1991

Fellow in Cardiovascular Medicine
The Cleveland Clinic Foundation
Cleveland, Ohio 1991-1992

Fellow in Interventional Cardiology
The Cleveland Clinic Foundation
Cleveland, Ohio 1992-1993

CERTIFICATION AND LICENSURE:

Medical Licensure: Ohio
License ~~—————~~ May 12, 1993

Board Certification: Diplomate, American Board of Internal Medicine,
September 13, 1989

Diplomate, Subspecialty of Cardiovascular Disease,
American Board of Internal Medicine
November 6, 1991
Recertification - November 7, 2001

Diplomate, Subspecialty of Interventional Cardiology
American Board of Internal Medicine
November 3, 1999

HONORS AND AWARDS:

Carnegie-Mellon University:

- Andrew Carnegie Society Scholarship for Carnegie Institute of Technology.
- Tau Beta Pi Honorary Engineering Fraternity.
- American Institute of Chemical Engineers Outstanding Student Award.
- Atlantic Richfield Award.
- Universal Oil Products Foundation Award.
- Babcock and Wilcox Aid to Education Award.
- American Society of Chemists Award.

Johns Hopkins University:

- Alpha Omega Alpha.
- Franklin Paine Mall Award for Cell Biology and Anatomy.
- Lange Medical Publishers Student Award.

University of Michigan:

- Fellow, American Heart Association (1991).
Michigan Affiliate
Research Project: Local Drug Delivery to Inhibit Arterial Response to Injury, ~~—————~~

Cleveland Clinic Foundation:

- 1992 Research Day Award for Clinical Fellows
- American College of Cardiology/Bristol Laboratories Affiliate Travel Award for 1993.

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

American College of Cardiology, Fellow
European Society of Cardiology, Fellow
American College of Physicians, Member
American Medical Association, Member
American Heart Association, Clinical Cardiology Council, Professional Member
Sigma Xi Scientific Research Society, Member

MANUSCRIPT REVIEWER:

Circulation
New England Journal of Medicine
Journal of the American Medical Association
Journal of the American College of Cardiology
Journal of Arteriosclerosis and Thrombosis
Thrombosis and Haemostasis
Circulation Research
Chest
American Journal of Cardiology
Coronary Artery Disease
American Heart Journal
Annals of Thoracic Surgery
Catheterization and Cardiovascular Interventions
Cleveland Clinic Journal of Medicine
The Medical Letter
Drugs and Aging
Geriatrics
American Hospital Formulary Service Drug Information

**APPEARS THIS WAY
ON ORIGINAL**

OTHER PROFESSIONAL ACTIVITIES:

Editorial Board: Circulation
Consulting Editor: American Journal of Cardiovascular Drugs
Editorial Board: American Heart Journal
Editorial Advisory Board: Acute Coronary Syndromes
Editorial Board: Journal of Invasive Cardiology
Editorial Board: Journal of Interventional Cardiology
Editorial Board: Cardiovascular Revascularization Medicine

Committee Member - American College of Cardiology / American Heart Association Writing Committee to Update 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction

Chairman, Scientific Advisory Board - PrognostiX Inc, Cleveland, Ohio
Member, Scientific Advisory Board - Mitsubishi Pharma Corporation, Osaka, Japan
Member - Friends of the Israel Heart Society

Reviewer - American College of Cardiology / American Heart Association 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction

Consultant - Accreditation Council for Graduate Medical Education (ACGME) - reviewer of program applications for residency training in internal medicine - interventional cardiology

Grant Reviewer - Department of Veterans Affairs' Medical Research Service

Abstract Reviewer - American College of Cardiology Scientific Sessions
Abstract Reviewer - American Heart Association Annual Scientific Sessions
Abstract Reviewer - International Congress on Coronary Artery Disease
Abstract Reviewer - International Meeting on Interventional Cardiology, Jerusalem, Israel

COMMITTEES:

Cleveland Clinic Lerner College of Medicine Curriculum Committee for 2nd Year Cardiopulmonary Block, 2004 to present
Steering Committee - Department of Veterans Affairs, Health Services Research and Development, Cardiac Care Follow-up Clinical Study, 2003
Cleveland Clinic Research Day Clinical Science Abstracts Committee 1995
Cleveland Clinic Tarazi Award Selection Committee 1995
Cleveland Clinic Interventional Cardiology Fellow Selection Committee 1994-2001

RESEARCH ACTIVITIES:

Ongoing Clinical Trials

Medical Director - Clinical Events Committee. Cleveland Clinic Cardiovascular Coordinating Center.

Principal Investigator - Steering Committee. A Randomized Evaluation in _____

Principal Investigator - Steering Committee. A Randomized Dose Ranging Study of _____

Principal Investigator - Steering Committee. A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of _____

Principal Investigator - Steering Committee. A Phase III Study of _____

Principal Investigator - Steering Committee. A Phase III Study of _____

Principal Investigator - Steering Committee. A Study Comparing _____

Principal Investigator - Steering Committee. A Study Comparing _____

Executive Steering Committee. A Randomized Comparison of _____

Principal Investigator - Operations Committee. A Phase III, Randomized, Open-Label Trial Evaluating the Efficacy and Safety of _____

Steering Committee. _____

Data Safety Monitoring Board. A Double-Blind, Placebo-Controlled, Randomized Phase III

Data Safety Monitoring Board. A Randomized, Double-Blind, Placebo-Controlled, Dose-
Ranging Multi-Center Study to Evaluate _____

Data Safety Monitoring Board. _____

Completed Clinical Trials

Principal Investigator - Steering Committee. Safety of Concomitant Therapy _____

Principal Investigator. _____

Principal Investigator. An Open-Label Study _____

The

Principal Investigator - Steering Committee. _____

Principal Investigator - Operations Committee. A Multicenter Randomized Trial Evaluating

Principal Investigator - Steering Committee. A Phase II Randomized, _____

Principal Investigator - Steering Committee. A Multi-Center, Double-Blind, _____

Steering Committee. _____

Principal Investigator - Steering Committee. The Effect of _____

Principal Investigator - Operations Committee. A Phase III Randomized, Double-Blind, Placebo-

Principal Investigator - Steering Committee. A Randomized, Double-Blind Evaluation of the

Principal Investigator - Operations Committee. A Phase II, Randomized, Double-Blind Trial

Principal Investigator - Steering Committee. A Randomized, Double-Blind Efficacy and Safety Evaluation of

Principal Investigator. Pilot Study: A Randomized Evaluation of

Co-Investigator. _____

Principal Investigator. _____

Principal Investigator - Steering Committee. _____

Principal Investigator - Steering Committee. _____

Clinical Investigator. Bypass Angioplasty Revascularization Investigation (BARI). National Heart, Lung, and Blood Institute, National Institutes of Health.

Data Safety Monitoring Board. A 12-Week Double-Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect _____

Data Safety Monitoring Board. A Randomized Placebo-Controlled Dose Finding Study of

Data Safety Monitoring Board.

Chairman, Data Safety Monitoring Board.

Co-Investigator. A Randomized, Double-Blind, Placebo-Controlled Study with Two

Co-Investigator. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical

Co-Investigator. Adequacy of Intracoronary Stent Deployment: Assessment by Intravascular Ultrasound.

Angiographer. Post Coronary Artery Bypass Study.

Preclinical Studies

Co-Principal Investigator. Biosynthetic Surfactants: A Novel Biomimetic Surface to Reduce Intra-Coronary Stent Complications. (Principal Investigator - _____ Ph.D., Department of Biomedical Engineering, Case Western Reserve University. Co-Principal Investigator - A. Michael Lincoff, M.D., Department of Cardiology, Cleveland Clinic Foundation. Co-Principal Investigator - _____ M.D., Ph.D., Department of Clinical Pathology, Cleveland Clinic Foundation) Whitaker Foundation/National Science Foundation.

Co-Investigator. Mechanisms of Arterial Restenosis after Balloon Angioplasty in the Diabetic Rat Model. Clinic Foundation Research Program Committee.

Co-Investigator. The Effect of Soluble Receptor for Advanced Glycation Endproducts (s-RAGE) on the Formation of Neointima Following Carotid Balloon Injury in the Diabetic Rat Model. Clinic Foundation Research Program Committee.

Co-Investigator. Comparative Study of the Pharmacokinetics and Pharmacodynamics of Soluble Receptor for Advanced Glycation Endproducts (s-RAGE) After Different Dosing Regimens and Routes of Administration in Zucker Diabetic Rats. Clinic Foundation Research Program Committee.

Co-Investigator. _____

Co-Investigator. _____

Co-Investigator. _____

Institute. _____ Genetics

Co-Investigator. _____

Co-Investigator. _____

Inc.

Co-Investigator. _____

Pharmaceuticals.

Co-Investigator. _____

Co-Investigator. _____

Principal Investigator. _____

Principal Investigator. _____

Co-Investigator. _____

Principal Investigator. _____

Principal Investigator. _____

Co-Investigator. _____

Co-Investigator. _____

Co-Investigator. Tyrosine Kinase Receptor Inhibition to Reduce Smooth Muscle Cell Reaction after Injury in the Rat Carotids. Cleveland Clinic Foundation Research Programs Committee.

Co-Investigator. _____

Co-Investigator. _____

Co-Investigator. _____

Co-Investigator. Role of Platelet Derived Growth Factor in the Response to Vascular Injury. A Study Using a Monoclonal Antibody to its Receptor. Clinic Foundation Research Program Committee.

Co-Investigator. _____

Co-Investigator. Pilot Study of Chlamydia Pneumonia Infestation, Cholesterol Feeding, and Copper Banding of Porcine Coronary Arteries as a Model of Coronary Plaque Rupture. Cleveland Clinic Foundation Research Program Committee.

Co-Investigator. _____

Co-Investigator. _____

Co-Investigator. _____

Co-Investigator. _____

Co-Investigator. _____

Co-Investigator. _____

Co-Investigator. _____

Co-Investigator. Early Proto-Oncogene Expression in Carotid Arteries of Diabetic Rats After Balloon Injury. Clinic Foundation Research Program Committee.

Co-Investigator. _____

BIBLIOGRAPHY:

Publications in Scientific Journals:

Peer Reviewed

1. Borovetz HS, Inskeep WH, **Lincoff AM**, Hardesty RL. Role of longitudinal diffusion in the extravascular pulmonary space on parameter estimates derived from data of multiple indicator dilution. *Physics in Medicine and Biology* 1982;27:819-835.
2. **Lincoff AM**, Borovetz HS, Inskeep WH. Characterization of the unsteady transport of labelled species in permeable capillaries: role of convective dispersion. *Physics in Medicine and Biology* 1983;28:1191-1208.
3. **Lincoff AM**, Borovetz HS, Hardesty RL. Regional pulmonary perfusion from dynamic computerized tomography. *American Institute of Chemical Engineers (AIChE) Symposium Series "Fundamentals in the Life Sciences"* 1983;79:131-8. Presented at the American Institute of Chemical Engineers Annual Meeting, 1983.
4. Neumann SJ, Sevick EM, **Lincoff AM**, Warty VS, Brant AM, Berceci SA, Herman IM, Borovetz HS. Experimental determination and mathematical model of the transient incorporation of cholesterol in the arterial wall. *Bulletin of Mathematical Biology*, 1990;52:711-732.
5. **Lincoff AM**, Popma JJ, Bates ER, Deeb GM, Meagher JS, Kelly AM, Wampler RK, Nicklas JM. Successful coronary angioplasty in two patients with cardiogenic shock using the Nimbus Hemopump support device. *American Heart Journal* 1990;120:970-972.
6. **Lincoff AM**, Popma JJ, Ellis SG, Vogel RA, Topol EJ. Percutaneous support devices for high-risk or complicated coronary angioplasty. *Journal of the American College of Cardiology*, 1991;17:770-780.
7. **Lincoff AM**, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic, and therapeutic profile. *Journal of the American College of Cardiology*, 1992;19:926-935.
8. **Lincoff AM**, Topol EJ, Chapekis AT, George BS, Candela RJ, Muller DWM, Zimmerman CA, Ellis SG. Intracoronary stenting compared with conventional therapy for abrupt vessel closure

- complicating coronary angioplasty: a matched case-control study. *Journal of the American College of Cardiology*, 1993;21:866-875.
9. **Lincoff AM**, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? *Circulation* 1993;87:1792-1805 (Erratum 1993;88:1361-1375).
 10. **Lincoff AM**, Topol EJ. Trickle-down thrombolysis. *Journal of the American College of Cardiology* 1993;21:1396-1398.
 11. Glass MG, Fuleihan F, Liao R, **Lincoff AM**, Chapados R, Jiang M, Hamlin R, Apstein CS, Allen PD, Ingwall JS, Hajjar RJ, Cory CR, O'Brien PJ, Gwathmey JK. Differences in cardioprotective efficacy of adrenergic receptor antagonists and Ca⁺² channel antagonists in an animal model of dilated cardiomyopathy. Effects on gross morphology, global cardiac function, and twitch force. *Circulation Research* 1993;73:1077-1089.
 12. **Lincoff AM**, Califf RM, Ellis SG, Sigmon KN, Lee KL, Topol EJ. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? *Journal of the American College of Cardiology* 1993;22:1780-1787.
 13. Jang Y, **Lincoff AM**, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. *Journal of the American College of Cardiology* 1994;24:1591-1601.
 14. **Lincoff AM**, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis: fact, fancy, and future. *Circulation* 1994;90:2070-2084.
 15. Ellis SG, **Lincoff AM**, George BS, Kereiakes DJ, Ohman EM, Krucoff MW, Califf RM, Topol EJ. Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. *Coronary Artery Disease* 1994;5:611-615.
 16. **Lincoff AM**, Topol EJ, Sigmon KN, Lee KL, Ohman EM, Rosenschein U, Califf RM, Ellis SG. Significance of a coronary artery with Thrombolysis in Myocardial Infarction grade 2 flow "patency" (Outcome in the Thrombolysis and Angioplasty in Myocardial Infarction trials). *American Journal of Cardiology* 1995;75:871-876.
 17. Ellis SG, Cowley MJ, Whitlow PL, Vandormael M, **Lincoff AM**, DiSciascio G, Dean LS, Topol EJ. Prospective case-control comparison of percutaneous transluminal coronary revascularization in patients with multivessel disease treated in 1986-87 versus 1991: improved in-hospital and 12-month results. Multivessel Angioplasty Prognosis Study (MAPS) Group. *Journal of the American College of Cardiology*, 1995;25:1137-1142.
 18. Harrington RA, **Lincoff AM**, Califf RM, Holmes DR, Berdan LG, O'Hanesian MA, Keeler GP, Garratt KN, Ohman EM, Mark DB, Jacobs AK, Topol EJ for the CAVEAT Investigators. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). *Journal of the American College of Cardiology* 1995;25:1693-1699.

19. Jang Y, Guzman L, **Lincoff AM**, Gottsauner-Wolf M, Forudi F, Hart CE, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in the rabbit atherosclerotic femoral artery injury model. *Circulation* 1995;92:3041-3050.
20. Harrington RA, Kleiman NS, Kottke-Marchant K, **Lincoff AM**, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, Greenberg CS, Kitt MM, Topol EJ, Califf RM. Immediate and reversible platelet inhibition following intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. *American Journal of Cardiology* 1995;76:1222-1227.
21. Califf RM, **Lincoff AM**, Tcheng JE, Topol EJ. An overview of the results of the EPIC trial. *European Heart Journal* 1995;16(Suppl L):43-49.
22. Ellis SG, Omoigui N, Bittl JA, **Lincoff AM**, Wolfe MW, Howell G, Topol EJ. Analysis and comparison of operator specific outcomes in interventional cardiology. From a multicenter database of 4860 quality-controlled procedures. *Circulation* 1996;93:431-439.
23. Shan K, **Lincoff AM**, Young JB. Anthracycline-induced cardiotoxicity: a maturing heart failure population? *Annals of Internal Medicine* 1996;125:47-58.
24. Van der Giessen WJ, **Lincoff AM**, Schwartz RS, van Beusekom HMM, Serruys PW, Holmes DR, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and biostable polymers in porcine coronary arteries. *Circulation*, 1996;94:1690-1697.
25. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, **Lincoff AM**, Yakubov SJ, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G. Effects of Integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: the importance of gender differences in response to antiplatelet therapy. *Circulation* 1996;94:2083-2089.
26. Guzman LA, Labhasetwar V, Song C, Jang Y, **Lincoff AM**, Levy RL, Topol EJ. Local intramural infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. *Circulation* 1996;94:1441-1448.
27. **Lincoff AM**, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LS, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ for the PROLOG Investigators. Standard versus low dose weight adjusted heparin in patients treated with the platelet GP IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. *American Journal of Cardiology* 1997;79:286-291.
28. Gottsauner-Wolf M, Jang Y, **Lincoff AM**, Cohen JL, Labhasetwar V, Poptic EJ, Forudi F, Guzman LA, DiCorleto PE, Levy RJ, Topol EJ, Ellis SG. Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth muscle cell proliferation in the rat carotid balloon injury model. *American Heart Journal* 1997;133:329-334.

29. **Lincoff AM**, Furst JG, Ellis SE, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. *Journal of the American College of Cardiology* 1997;29:808-816.
30. Gottsauner-Wolf M, Jang Y, Penn MS, Kaplan A, Ellis SG, Chisolm GM, Topol EJ, **Lincoff AM**. Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. *Catheterization and Cardiovascular Diagnosis* 1997;42 ;102-108.
31. The IMPACT II Investigators (collaborative group "silent" **co-authored** paper). Effects of Integrilin™, a platelet glycoprotein IIb/IIIa inhibitor, in preventing ischemic complications of percutaneous coronary intervention. *Lancet* 1997;349:1422-1428.
32. **The EPILOG Investigators** (collaborative group "silent" **first-authored** paper). Platelet glycoprotein IIb/IIIa receptor inhibition with abciximab with lower heparin dosages during percutaneous coronary revascularization. *New England Journal of Medicine* 1997;336:1689-1696.
33. **Lincoff AM**, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ for the EPIC Investigators. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by c7E3 Fab (abciximab) among patients with unstable angina undergoing percutaneous coronary revascularization. *Journal of the American College of Cardiology* 1997;30:149-156.
34. **Lincoff AM**. Does stenting prevent diabetic arterial shrinkage after percutaneous coronary revascularization? *Circulation* 1997;96:1374-1377.
35. **Lincoff AM**, Topol EJ, Califf RM. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty- Reply. *New England Journal of Medicine* 1997;23:1244.
36. Van der Giessen WJ, Van Beusekom HMM, Serruys PW, **Lincoff AM**, Ellis SG, Topol EJ, Schwartz RS, Holmes DR. Inflammatory response to coronary artery stenting - Response. *Circulation* 1997;96:2092-2093.
37. Shan K, **Lincoff AM**. Anthracycline-induced cardiotoxicity - Response. *Annals of Internal Medicine* 1997;126:827-828.
38. Kereiakes DJ, **Lincoff AM**, Miller DP, Tchong JE, Cabot CF, Anderson KM, Weisman HF, Califf RM, Topol EJ, for the EPILOG Investigators. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent utilization, clinical outcomes, and bleeding complications. *Circulation* 1998;97:857-864.
39. Kleiman NS, **Lincoff AM**, Kereiakes DJ, Miller DP, Aguirre FV, Anderson K, Weisman HF, Califf RM, Topol EJ. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. *Circulation* 1998;97:1912-1920.
40. Ghaffari S, Kereiakes DJ, **Lincoff AM**, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. *American Journal of Cardiology* 1998;82:7-12.

41. Mandak JS, Blankenship JC, Gardner LH, Berkowitz SD, Aguirre FV, Sigmon KN, Timmis GC, Gilchrist IC, McIvor M, Resar J, Weiner BH, George BS, Talley JD, **Lincoff AM**, Tcheng JE, Califf RM, Topol EJ. Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide. *Journal of the American College of Cardiology* 1998;31:1518-1524.
42. The EPISTENT Investigators (collaborative group "silent" **co-authored** paper). Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. *Lancet* 1998;352:87-92.
43. The PURSUIT Trial Investigators (collaborative group "silent" **co-authored** paper). Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: a randomized, placebo-controlled, clinical trial. *New England Journal of Medicine* 1998;339:436-443.
44. Steinhubl SR, Lauer MS, Mukherjee DP, Moliterno DJ, **Lincoff AM**, Ellis SG, Topol EJ. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure related non-Q-wave myocardial infarctions. *Journal of the American College of Cardiology* 1998;32:1366-1370.
45. Bhatt DL, **Lincoff AM**, Kereiakes DJ, Tcheng JE, Godfrey N, Califf RM, Topol EJ. Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. *American Journal of Cardiology* 1998;82:1105-1106.
46. Ellis SG, **Lincoff AM**, Miller D, Tcheng JE, Kleiman NS, Kereiakes D, Califf R, Topol EJ for the EPIC and EPILOG Investigators. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. *Journal of the American College of Cardiology* 1998;32:1619-1623.
47. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, Tcheng JE, **Lincoff AM**, Hasselblad V, Topol EJ. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. *Circulation* 1998;98:2829-2835.
48. Topol EJ, **Lincoff AM**, Sapp S. Coronary stenting and use of abciximab - reply. *Lancet* 1998;352:1311-1312.
49. Smith JW, Steinhubl SR, **Lincoff AM**, Coleman J, Lee T, Hillman RS, Collier BS. The rapid platelet function assay (RPFA): an automated and quantitative cartridge-based method. *Circulation* 1999;99:620-625.
50. Thel MC, Califf RM, Tcheng JE, Sigmon KN, **Lincoff AM**, Topol EJ, Ellis SG, for the EPIC Investigators. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC Trial. *American Heart Journal* 1999;137:264-273.
50. Harrington RA, Califf RM, Holmes DR, Pieper KS, **Lincoff AM**, Berdan LG, Thompson TD, Topol EJ for the CAVEAT-I Investigators. Is all unstable angina the same? Insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). *American Heart Journal*, 1999;137:227-33.

51. Alexander JH, Harrington RA, Tuttle R, Berdan LG, **Lincoff AM**, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt MM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Widimsky P, Boland JB, Armstrong PW, on behalf of the PURSUIT Investigators. Prior aspirin use predicts worse 30-day outcomes in patients with non-ST-elevation acute coronary syndromes: insights from PURSUIT. *American Journal of Cardiology* 1999;83:1147-1151.
52. Tardiff BE, Califf RM, Tchong JE, **Lincoff AM**, Sigmon KN, Harrington RA, Mahaffey KW, Ohman EM, Teirstein PS, Blankenship J, Kitt MM, Topol EJ for the IMPACT II Investigators. Clinical outcomes after detection of elevated creatine kinase MB in patients undergoing percutaneous intervention. *Journal of the American College of Cardiology* 1999;33:88-96.
53. **Lincoff AM**, Tchong JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ for the EPILOG Investigators. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one year outcome in the EPILOG trial. *Circulation* 1999;99:1951-1958.
54. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, Rosenthal ML, Godfrey NK, Collier BS, Topol EJ, **Lincoff AM**. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. *Circulation* 1999;100:1977-1982.
55. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller JM, Sloan MA, Berdan LG, MacAulay CM, **Lincoff AM**, Deckers J, Topol EJ, Califf RM, for the PURSUIT Investigators. Stroke in patients with acute coronary syndromes. Incidence and outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. *Circulation* 1999;99:2371-2377.
56. **Lincoff AM**, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ for the EPISTENT Investigators. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. *New England Journal of Medicine* 1999;341:319-327.
57. Topol EJ, Mark DB, **Lincoff AM**, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson K, Califf RM, on behalf of the EPISTENT Investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. *Lancet* 1999;354:2019-2024.
58. Marso SP, **Lincoff AM**, Ellis SG, Bhatt DL, Tanguay J-F, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT diabetic substudy. *Circulation* 1999;100:2477-2484.
59. McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, **Lincoff AM**, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM, Harrington RA, for the PURSUIT Investigators. The clinical significance of thrombocytopenia during a non-ST elevation acute coronary syndrome: the PURSUIT experience. *Circulation* 1999;2892-2900.

60. Ellis SG, Miller D, Keys TF, Brown K, Ellert R, Howell G, **Lincoff AM**, Topol EJ. Comparing physician-specific two-year patient outcomes after coronary angiography: methodologic issues and results. *Journal of the American College of Cardiology* 1999;33:1278-1285.
61. Robbins MA, Marso SP, Wolski K, Peterson J, **Lincoff AM**, Brener S. Chest pain - a strong predictor of adverse cardiac events following percutaneous coronary intervention (from the Evaluation of Platelet IIb/IIIa Inhibition for Stenting trial [EPISTENT]). *American Journal of Cardiology* 1999;84:1350-1353.
62. Gilchrist IC, Gardner LH, Muhlstein JB, Arnold AM, **Lincoff AM**, Califf RM, Tcheng JE, Topol EJ. The effect of institutional volume and academic status on outcomes of coronary intervention: the IMPACT II experience. *American Heart Journal* 1999;138:976-982.
63. Simoons ML, van den Brand M, **Lincoff AM**, Harrington R, van der Wieken R, Vahanian A, Rutsch W, Kootstra J, Boersma E, Califf RM, Topol EJ. Minimal myocardial damage during coronary intervention is associated with impaired outcome. *European Heart Journal* 1999;20:1112-1119.
64. Holmes D, Fitzgerald P, Goldberg S, LaBlanche J-M, **Lincoff AM**, Savage M, Serruys PW, Willerson J, Granet JR, Chan R, Poland M. The PRESTO protocol. Prevention of Restenosis with Tranilast and its Outcomes: A double-blind placebo controlled trial. *Am Heart Journal* 2000;139:23-31.
65. Mark DB, Harrington RA, **Lincoff AM**, Califf RM, Nelson CL, Tsiatis AA, Buell H, Mahaffey KW, Davidson-Ray L, Topol EJ. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST elevation acute coronary syndromes. *Circulation* 2000;101:366-371.
66. Kleiman NS, **Lincoff AM**, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, Lorenz TJ, Simoons ML, Boersma E, Topol EJ, Califf RM, Harrington RA, for the PURSUIT Investigators. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. *Circulation* 2000;101:751-757.
67. Thel MC, Califf RM, Tardiff BE, Gardner LH, Sigmon KN, **Lincoff AM**, Topol EJ, Kitt MM, Blankenship JC, Tcheng JE, for the IMPACT II Investigators. Timing of and risk factors for myocardial ischemic events after percutaneous coronary interventions: insights from IMPACT-II. *American Journal of Cardiology* 2000;85:427-434.
68. Bhatt DL, Marso SP, **Lincoff AM**, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. *Journal of the American College of Cardiology* 2000;35:922-928.
69. **Lincoff AM**, Califf RM, Topol EJ. Intravenous platelet glycoprotein IIb/IIIa receptor blockade in cardiovascular disease. *Journal of the American College of Cardiology* 2000;35:1103-1115.
70. Bhatt DL, **Lincoff AM**, Califf RM, Simoons ML, Tcheng JE, Brener SJ, Wolski KE, Topol EJ. The benefit of abciximab in percutaneous coronary revascularization is not device-specific. *American Journal of Cardiology* 2000;85:1060-1064.

71. Akkerhuis KM, Deckers JW, Harrington RA, Stepinska J, Mahaffey KW, Wilcox RG, **Lincoff AM**, Keltai M, Topol EJ, Califf RM, Simoons ML, for the PURSUIT Investigators. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: results from PURSUIT. *European Heart Journal* 2000;21:339-42.
72. Cura F, Bhatt DL, **Lincoff AM**, Kapadia SR, L'Allier PL, Ziada KM, Wolski KE, Moliterno DJ, Brener SJ, Ellis SG, Topol EJ. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. *Circulation* 2000;102:28-34.
73. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, **Lincoff AM**, Califf RM, Topol EJ, Simoons ML, for the PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST segment elevation: results from an international trial of 9461 patients. *Circulation* 2000;101:2557-2567.
74. The SPEED Trial Investigators (collaborative group "silent" **co-authored** paper). Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction. *Circulation* 2000;101:2788-2794.
75. **Lincoff AM**, Topol EJ. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven? *European Heart Journal* 2000;21:863-867.
76. Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf RM, **Lincoff AM**. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender. *Journal of the American College of Cardiology* 2000;36:381-386.
77. Kereiakes DJ, Berkowitz SK, **Lincoff AM**, Tcheng JE, Wolski K, Achenbach R, Melsheimer R, Anderson K, Califf RM, Topol EJ. Clinical correlates and clinical course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. *American Heart Journal* 2000;140:74-80.
78. **Lincoff AM**, LeNarz RA, Despotis GJ, Smith PK, Booth JE, Raymond RE, Sapp SK, Cabot CF, Tcheng JE, Califf RM, Effron MB, Topol EJ for the EPILOG and EPISTENT Investigators. Abciximab and bleeding complications during coronary surgery: results from the EPILOG and EPISTENT trials. *Annals of Thoracic Surgery* 2000;70:516-526.
79. Steinhubl SR, Moore SA, **Lincoff AM**. Abciximab (ReoPro) removal during cardiopulmonary bypass with a hemoconcentrator. *Journal of Thoracic and Cardiovascular Surgery* 2000;119:401-402.
80. **Lincoff AM**, Harrington RA, Califf RM, Hochman JS, Guerci AD, Ohman EM, Pepine CJ, Kopecky SL, Kleiman NS, Pacchiana CM, Berdan LG, Kitt MM, Simoons ML, Topol EJ, for the PURSUIT Trial Investigators. Management of patients with acute coronary syndromes in the United States using glycoprotein IIb/IIIa inhibition: insights from the PURSUIT trial. *Circulation* 2000;102-1093-1100.

81. Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, **Lincoff AM**, Simoons ML, Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ, for the PURSUIT Investigators. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. *Circulation* 2000;102:1101-1106.
82. **Lincoff AM**. Stent scrutiny. *Journal of the American Medical Association* 2000;284:1839-1841.
83. **Lincoff AM**, Mark DB, Tchong JE, Califf RM, Bala MV, Anderson KM, Davidson-Ray L, Knight JD, Cabot CF, Topol EJ, for the EPILOG Investigators. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab with low-dose heparin during percutaneous coronary revascularization. Results from the EPILOG randomized trial. *Circulation* 2000;102:2923-2929.
84. Hermann HC, Moliterno DJ, Ohman EM, Stebbins A, Bode C, Betriu C, Forycki F, Miklin JS, Bachinsky WB, **Lincoff AM**, Califf RM, Topol EJ. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO 4 Pilot) trial. *Journal of the American College of Cardiology* 2000;36:1489-1496.
85. ESPRIT Investigators (collaborative group "silent" **co-authored** paper). The ESPRIT study: a randomised, placebo-controlled trial of a novel dosing regimen of eptifibatid in planned coronary stent implantation. *Lancet* 2000;356:2037-2044.
86. Steinhubl SR, Kottke-Marchant K, Moliterno DL, Rosenthal M, Topol EJ, **Lincoff AM**, Collier BS. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in patients undergoing percutaneous coronary intervention - Response. *Circulation* 2000;102:E186.
87. Peterson JG, Topol EJ, Sapp SK, Young JB, **Lincoff AM**, Lauer MS. Evaluation of the effects of aspirin combined with angiotensin converting enzyme inhibitors in patients with coronary artery disease. *American Journal of Medicine* 2000;109:371-377.
88. Greenbaum AB, Harrington RA, Hudson MP, MacAulay CM, Wilcox RG, Simoons ML, Berdan LG, Guerci A, Cokkinos DV, Kitt MM, **Lincoff AM**, Topol EJ, Califf RM, Ohman EM, for the PURSUIT Investigators. Therapeutic value of eptifibatid at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. *Journal of the American College of Cardiology* 2001;37:492-498.
89. Chew DP, Bhatt DL, **Lincoff AM**, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting time during percutaneous coronary intervention. *Circulation* 2001;103:961-966.
90. Popma JJ, Ohman EM, Weitz J, **Lincoff AM**, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. *Chest* 2001;119:321S-336S.
91. Steinhubl SR, Ellis SG, Wolski K, **Lincoff AM**, Topol EJ, for the EPISTENT Investigators. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events. Data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. *Circulation* 2001;103:1403-1409.

92. Cho L, Bhatt DL, Wolski K, **Lincoff AM**, Topol EJ, Moliterno DJ. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: pooled analysis from EPIC, EPILOG, and EPISTENT. *American Heart Journal* 2001;141:599-602.
93. Peterson JG, Topol EJ, Roe MT, Sapp SK, **Lincoff AM**, Deckers JW, Lauer MA, Harrington RA, Califf RM, Lauer MS, on behalf of the PURSUIT Investigators. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. *American Journal of Cardiology* 2001;87:532-536.
94. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, **Lincoff AM**, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. *Lancet* 2001;357:1063-1068.
95. Steinhubl SR, Talley JD, Braden GA, Tchong JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, Popma JJ, Dangas G, Gallo R, Sane DC, Saucedo JF, Jia G, **Lincoff AM**, Theroux P, Holmes DR, Teirstein PS, Kereiakes DJ. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event following percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) multicenter study. *Circulation* 2001;103:2572-2578.
96. The GUSTO V Investigators (collaborative group "silent" **co-authored** paper). Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. *Lancet* 2001;357:1905-1914.
97. Akkerhuis KM, Deckers JW, **Lincoff AM**, Tchong JE, Boersma E, Anderson K, Balog C, Califf RM, Topol EJ, Simoons ML. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. *Journal of the American Medical Association* 2001;286:78-82.
98. **Lincoff AM**, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers following percutaneous coronary revascularization. *Circulation* 2001;104:163-167.
99. Tardiff BE, Jennings L, Harrington RA, Gretler D, Potthoff RF, Vorchheimer DA, Eisenberg PR, **Lincoff AM**, Labinaz MA, Joseph DM, McDougal MF, Kleiman NS, for the PERIGEE Investigators. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. *Circulation* 2001;104:399-405.
100. Park S-H, Marso SP, Zhou Z, Forudi F, Topol EJ, **Lincoff AM**. Neointimal hyperplasia following arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. *Circulation* 2001;104:815-819.
101. Tchong JE, Kereiakes DJ, **Lincoff AM**, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, Efron MB, Braden GA on behalf of the ReoPro Readministration Registry Investigators. Abciximab readministration: results of the ReoPro Readministration Registry. *Circulation* 2001;104:870-875.

102. Wang K, Zhou Z, Zhou X, Tarakji K, Topol EJ, **Lincoff AM**. Prevention of intimal hyperplasia with recombinant soluble P-selectin ligand Ig (rPSGL-Ig) in the porcine coronary artery balloon injury model. *Journal of the American College of Cardiology* 2001;38:577-582.
103. Ellis SG, Brener SJ, **Lincoff AM**, Moliterno DJ, Whitlow PL, Schneider JP, Topol EJ. Beta-blockers before percutaneous coronary intervention do not attenuate post-procedural creatine kinase isoenzyme rise. *Circulation* 2001;104:2685-2688.
104. Lauer MA, Houghtaling PL, Peterson JG, Granger CB, Bhatt DL, Sapp SK, Simoons ML, Harrington RA, Topol EJ, **Lincoff AM**. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes. Observations from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. *Circulation* 2001;104:2772-2777.
105. Tcheng JE, Talley JD, O'Shea JC, Gilchrist IC, Kleiman NS, Grines CL, Davidson CJ, **Lincoff AM**, Califf RM, Jennings LK, Kitt MM, Lorenz TJ. Clinical pharmacology of higher-dose eptifibatide in percutaneous coronary intervention: results of the PRIDE study. *American Journal of Cardiology* 2001;88:1097-1102.
106. Chew DP, Bhatt DL, **Lincoff AM**, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ. Defining the optimal activated clotting times during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials - response. *Circulation* 2001;104:E124.
107. Ronner E, Boersma E, Akkerhuis KM, Harrington RA, **Lincoff AM**, Deckers JW, Armstrong PW, Karsch K, Kleiman NS, Vahanian A, Topol EJ, Califf RM, Simoons ML. Patients with acute coronary syndromes without persistent ST-elevation undergoing percutaneous coronary intervention benefit most of early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. *European Heart Journal* 2002;23:239-246.
108. Zhou Z, Lauer MA, Wang K, Forudi F, Zhou X, Song X, Solowski N, Kapadia SR, Nakada MT, Topol EJ, **Lincoff AM**. Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. *Atherosclerosis* 2002;161:153-159.
109. Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, **Lincoff AM**, Simoons ML. Minor myocardial damage and prognosis. Are spontaneous and percutaneous coronary intervention-related events different? *Circulation* 2002;105:554-556.
110. Mazur W, Kaluza GI, Sapp S, Balog C, Topol EJ, Mark DB, Ellis SG, Kereiakes DJ, **Lincoff AM**, Kleiman NS. Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists. *American Heart Journal* 2002;143:594-601.
111. Yoon J, Wu C-J, Homme J, Tuch RJ, Wolff RG, Topol EJ, **Lincoff AM**. Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in the porcine coronary artery injury model. *Yonsei Medical Journal* 2002;43:242-251.

112. Jeremias A, Bhatt DL, Chew DP, Ziada KM, Albirini A, Brener SJ, **Lincoff AM**, Topol EJ, Ellis SG. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. *American Journal of Cardiology* 2002; 89:1209-1211.
113. Islam MA, Blankenship JC, Balog C, Iliadis EA, **Lincoff AM**, Tcheng JE, Califf RM, Topol EJ. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). *American Journal of Cardiology* 2002;90:916-921.
114. Ouzan J, Perault C, **Lincoff AM**, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. *American Journal of Hypertension* 2002;15:333-339.
115. **Lincoff AM**, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization. *American Heart Journal* 2002;146:847-53.
116. Topol EJ, **Lincoff AM**, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, Tcheng JE, Sapp S, Califf RM, for the EPIC, EPILOG, and EPISTENT Investigators. Multiyear follow-up of abciximab therapy in three randomized placebo-controlled trials of percutaneous coronary revascularization. *American Journal of Medicine* 2002;113:1-6.
117. Chang WC, Harrington RA, Simoons ML, Califf RM, **Lincoff AM**, Armstrong PW, for the PURSUIT Investigators. Does eptifibatid confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? *European Heart Journal* 2002;23:1102-1111.
118. Lev EI, Marmur JD, Zdravkovic M, Osende JI, Robbins J, Delfin JA, Richard M, Erhardtsen E, Thomsen MS, **Lincoff AM**, Badimon JJ. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa. An ex vivo human study. *Arteriosclerosis Thrombosis and Vascular Biology* 2002;22:1036-1041.
119. Wang K, Zhou X, Zhou Z, Tarakji K, Qin JX, Sitges M, Shiota T, Forudi F, Schaub RG, Kumar A, Penn MS, Topol EJ, **Lincoff AM**. Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion. *Thrombosis and Haemostasis* 2002;88:149-154.
120. Holmes DR, Savage M, Lablanche JM, Grip L, Seruys PW, Fitzgerald PJ, Fischman D, Goldberg S, Brinker JA, Zeiher AM, Shapiro LM, Willerson JT, Davis BR, Ferguson JJ, Popma J, King SB, **Lincoff AM**, Tcheng JE, Chan R, Granett JR, Poland M. Results of Prevention of REStensosi with Tranililast and its Outcomes (PRESTO) trial. *Circulation*. 2002;106:1243-1250.
121. Kereiakes DJ, **Lincoff AM**, Anderson KM, Achenbach R, Patel K, Barnathan E, Califf RM, Topol EJ, on behalf of the EPIC, EPILOG, and EPISTENT Investigators. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. *American Journal of Cardiology* 2002;90:628-630.
122. Gurm HS, Brennan DM, Booth J, Tcheng JE, **Lincoff AM**, Topol EJ. Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). *American Journal of Cardiology* 2002;90:42-5.

123. Blankenship JC, Balog C, Sapp SK, Califf RM, **Lincoff AM**, Tcheng JE, Topol EJ. Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. *Catheterization & Cardiovascular Interventions* 2002;57:476-83.
124. Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, **Lincoff AM**, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW, Harrington RA. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. *Circulation* 2002;105:2385-91.
125. Ellis SG, **Lincoff AM**, Whitlow PL, Raymond R, Franco I, Schneider J, Topol EJ. Evidence that angiotensin converting enzyme inhibitor use diminishes coronary revascularization after stenting - an observational study of 1562 consecutively treated patients. *American Journal of Cardiology* 2002;89:937-940.
126. Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Topol EJ, **Lincoff AM**, Wang K. Administration of recombinant P-selectin glycoprotein ligand Fc fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model. *Arteriosclerosis Thrombosis and Vascular Biology* 2002;22:1598-1603.
127. **Lincoff AM**, Califf RM, van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowsky Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ, for the GUSTO V Investigators. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy versus conventional fibrinolytic therapy for acute myocardial infarction: the GUSTO V randomized trial. *Journal of the American Medical Association* 2002;288:2130-2135.
128. Mukherjee D, Gurm H, Tang WH, Roffi M, Wolski K, Moliterno DJ, Guetta V, Ardissino D, Bode C, Steg G, **Lincoff AM**, and Topol EJ. Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery treated with combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. *American Journal of Cardiology* 2002;90:1198-1203.
129. **Lincoff AM**, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ for the REPLACE-2 Investigators. Bivalirudin and provision glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. *Journal of the American Medical Association* 2003;289:853-863.
130. Cho L, Chew DP, Moliterno DJ, Roffi M, Ellis SG, Franco I, Bajzer C, Bhatt DL, Dorosti K, Simpfendorfer C, Tuzcu M, Yadav JS, Brener S, Raymond R, Whitlow P, Topol EJ, **Lincoff AM**. Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive GP IIb/IIIa receptor inhibition. *American Journal of Cardiology* 2003;91:742-743.

131. Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan, Jr. TJ, Breall JA, PhD, Moses JW, Eaton GM, Sklar MA, and **Lincoff AM**. Safety of concomitant therapy with eptifibatid and enoxaparin in patients undergoing percutaneous coronary intervention - results of the Coronary Revascularization Using Integrilin and Single Bolus Enoxaparin study. *Journal of the American College of Cardiology* 2003;41:20-25.
132. **Lincoff AM**. Important triad in cardiovascular medicine - diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade. *Circulation* 2003;107:1556-1559.
133. Wang K, Zhou X, Zhou Z, Tarakji K, Carneiro M, Penn MS, Murray D, Klein A, Humphries RG, Turner J, Thomas JD, Topol EJ, **Lincoff AM**. Blockade of platelet P2Y₁₂ receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. *Atherosclerosis, Thrombosis, and Vascular Biology* 2003;23:357-362.
134. Wang K, Kessler PD, Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Kibbe M, Kovesdi I, Brough DE, Topol EJ, **Lincoff AM**. Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. *Molecular Therapy* 2003;7:597-603.
135. Cho L, Kottke-Marchant K, **Lincoff AM**, Roffi M, Reginelli JP, Kaldus T, Moliterno DJ. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. *American Journal of Cardiology* 2003;91:1110-1113.
136. Rao SV, Kaul P, Newby LK, **Lincoff AM**, Hochman J, Harrington RA, Mark DB, Peterson ED. Poverty, process of care, and outcome in acute coronary syndromes. *Journal of the American College of Cardiology* 2003;41:1948-1954.
137. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X, Lu Y, Stern DM, Schmidt AM, **Lincoff AM**, Topol EJ. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. *Circulation* 2003;107:2238-2243.
138. Tcheng JE, Madan M, O'Shea C, Cohen EA, Buller CE, **Lincoff AM**, Popma JJ, Teirstein PS, Kitt MM, Lorenz TJ, Greenberg S, Fost N, Califf RM, for the ESPRIT Investigators. Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention. *Journal of Interventional Cardiology* 2003;16:97-105.
139. Bhatt DL, Chew DP, **Lincoff AM**, Simoons ML, Harrington RA, Ommen SR, Jia G, Topol EJ on behalf of the PURSUIT Investigators. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. *American Journal of Cardiology* 2003;92:136-140.
140. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, **Lincoff AM**, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. *Journal of the American Medical Association* 2003;290:898-904.

141. Gurm HS, Bhatt DL, **Lincoff AM**, Tcheng JE, Kereiakes DJ, Kleiman NS, Jia G, Topol EJ. Impact of preprocedural white blood cell count on long-term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials. *Heart* 2003;10:1200-1204.
142. Savonitto S, Armstrong PW, **Lincoff AM**, Jia G, Sila CA, Booth J, Terrosu P, Cavallini C, White HD, Ardissino D, Califf RM, Topol EJ for the GUSTO V Investigators. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. *European Heart Journal* 2003;24:1807-1814.
143. Chew DP, Bhatt DL, Kimball W, Henry TD, Berger P, McCullough PA, Feit F, Bittl JA, **Lincoff AM**. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. *American Journal of Cardiology* 2003;92:919-923.
144. Khot UN, Jia G, Moliterno DJ, **Lincoff AM**, Khot MB, Harrington RA, Topol EJ. Prognostic importance of physical examination for heart failure in non-ST elevation acute coronary syndromes: the enduring value of Killip classification. *Journal of the American Medical Association* 2003;290:2174-2181.
145. **Lincoff AM**, Topol EJ. Glycoprotein IIb/IIIa inhibition in percutaneous coronary interventions (letter response). *Journal of the American Medical Association* 2003;290:1451.
146. Alexander JH, Harrington RA, Bhapkar M, Mahaffey KW, **Lincoff AM**, Ohman EM, Klotwijk P, Pahlm O, Henden B, Deckers JW, Simoons ML, Califf RM, Wagner GS. Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. *American Journal of Medicine* 2003;11:613-619.
147. Mukherjee D, Hsu A, Moliterno DJ, **Lincoff AM**, Goormastic M and Topol EJ. Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients <40 years of age. *American Journal of Cardiology* 2003;92:1465-1467.
148. Aronow HD, Navaro GM, Lauer MS, Brennan DM, **Lincoff AM**, Topol EJ, Kereiakes DJ, Nissen SE. In-hospital initiation of lipid-lowering therapy following coronary intervention is the strongest predictor of long-term utilization: a propensity analysis. *Archives of Internal Medicine* 2003;163:2576-2582.
149. Ellis K, Tcheng JE, Sapp S, Topol EJ, **Lincoff AM**. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the EPIC, EPILOG, EPISTENT, CAPTURE and RAPPORT Trials. *Journal of Interventional Cardiology* 2003;16:299-305.
150. Gurm HS, **Lincoff AM**, Lee D, Tang WHW, Jia G, Booth JE, Califf RM, Ohman EM, Van de Werf F, Armstrong PW, Guetta V, Wilcox R, Topol EJ. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition; lessons from the GUSTO V trial. *Journal of the American College of Cardiology* 2004;43:542-548.

151. Koster A, Spiess B, Chew DP, Krabatsch T, Tambour L, DeAnda A, Hetzer R, Kuppe H, Smedira NG, **Lincoff AM**. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. *American Journal of Cardiology* 2004;93:356-359.
152. **Lincoff AM**. Coupling drug and catheter therapy for myocardial infarction. *Journal of the American Medical Association* 2004;291:1000-1002.
153. Dery J-P, Braden GA, **Lincoff AM**, Kereiakes DJ, Browne K, Little T, George BS, Sane DC, Cines DB, Effron MB, Mascelli MA, Langrall MA, Damaraju L, Barnathan ES, Tchong JE, on behalf of the ReoPro Readministration Registry Investigators. Rinal results of the ReoPro readministration registry. *American Journal of Cardiology* 2004;93:979-984.
154. **Lincoff AM**, Bittl JA, Kleiman NS, Sarembock I, Jackman D, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann III J, Parker G, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP, Topol EJ, for the REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). *American Journal of Cardiology* 2004;93:1092-1096.
155. Alexander JH, Dyke CK, Yang H, Becker RC, Hasselblad V, Zillman LA, Kleiman NS, Hochman JS, Berger PB, Cohen EA, **Lincoff AM**, Saint-Jacques H, Chetcuti S, Burton JR, Buerigler JM, Spence FP, Shimoto Y, Robertson TL, Kunitada S, Bovill EG, Armstrong PW, Harrington RA on behalf of the XaNADU-PCI Investigators. *Journal of Thrombosis and Haemostasis* 2004;2:234-241.
156. Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, Lansky AJ, **Lincoff AM**, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. *American Heart Journal* 2004;148:269-276.
157. Gurm HS, **Lincoff AM**, Kleiman NS, Kereiakes DJ, Tchong JE, Aronow HD, Askari AT, Brennan DM, Topol EJ. The double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions. *Journal of the American College of Cardiology* 2004;94:30-34.
158. Brener SJ, Moliterno DJ, **Lincoff AM**, Steinhubl SR, Wolski KE, Topol EJ. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. *Circulation* 2004;110:994-998.
159. Rajagopal V, Gurm HS, Bhatt DL, **Lincoff AM**, Tchong JE, Kereiakes DJ, Kleiman NS, Jia G, Topol EJ. Elevated WBC count after percutaneous coronary intervention correlates with an increased risk of long-term mortality. *American Journal of Cardiology* 2004;94: 190-92.

160. **Lincoff AM**, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ for the REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade versus heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. *Journal of the American Medical Association* 2004;292:696-703.
161. Roe MT, Mahaffey KW, Kilaru R, Alexander JH, Akkerhuis KM, Simoons ML, Harrington RA, Tardiff BE, Granger CB, Ohman EM, Moliterno DJ, **Lincoff AM**, Armstrong PW, Van de Werf F, Califf RM, Topol EJ. Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. *European Heart Journal* 2004;25:313-321.
162. Ellis SG, Bajzer CT, Bhatt DL, Brener SJ, Whitlow PL, **Lincoff AM**, Moliterno DJ, Raymond RE, Tuzcu EM, Franco I, Dushman-Ellis S, Lander KJ, Schneider JP, Topol EJ. Real-world bare metal stenting: Identification of patients at low or very low risk of 9-month coronary revascularization. *Catheterization and Cardiovascular Interventions* 2004;63:135.
163. Saw J, **Lincoff AM**, Desmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ for the REPLACE-2 Investigators. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional GP IIb/IIIa blockade compared to heparin with routine GP IIb/IIIa blockade: a REPLACE-2 substudy. *Journal of the American College of Cardiology* 2004;44:1194-1199.
164. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouth ME, Feit F, Lansky AJ, **Lincoff AM**, Mehran R, Moses JW, Ohman M, White HD. Acute Catheterization and Urgent Intervention Triage strategy (ACUTY) trial: study design and rationale. *American Heart Journal* 2004;148:764-775.
165. Cohen DJ, **Lincoff AM**, Lavelle TA, Chen H-L, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ on behalf of the REPLACE-2 Investigators. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention. Results from the REPLACE-2 trial. *Journal of the American College of Cardiology* 2004;44:1792-1800.
166. Tang WHH, **Lincoff AM**. Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa blockade. The triad revisited. *Circulation* 2004;110:3618-3620.
167. Chiu JH, Bhatt DL, Ziada KM, Chew DP, Whitlow PL, **Lincoff AM**, Ellis SG, Topol EJ. Impact of female sex on outcome after percutaneous coronary intervention. *American Heart Journal* 2004;148:998-1002.
168. Gurm HS, Rajagopal V, Fathi R, Vivekananthan D, Yadav JS, Bhatt DL, Ellis SG, **Lincoff AM**, Topol EJ. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. *American Journal of Cardiology* 2005;95:716-721.

169. Alexander JH, Yang H, Becker RC, Kodama K, Goodman S, Dyke CK, Kleiman NS, Hochman JS, Berger PB, Cohen EA, **Lincoff AM**, Burton JR, Bovill EG, Kawai C, Armstrong PW, Harrington RA, on behalf of the XaNADU-ACS Investigators. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS trial. *Journal of Thrombosis and Haemostasis* 2005;3:439-447.
170. Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman NJ, Feit F, Wolski K, Bittl JA, Wilcox R, Topol EJ, **Lincoff AM** for the REPLACE-2 Investigators. Use of Bivalirudin During Percutaneous Coronary Intervention in Patients with Diabetes Mellitus. An Analysis from the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE) -2 Trial. *Journal of the American College of Cardiology* 2005;45:1932-1938.
171. Brener SJ, **Lincoff AM**, Bates ER, Jia G, Armstrong PW, Guetta V, Hochman JS, Savonitto S, Wilcox RG, White HD, Topol EJ for the GUSTO V Investigators. The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: Insights from the GUSTO V Trial. *American Heart Journal* 2005;150:89-93.
172. Roe MT, Marso SP, Peterson JG, Sapp SK, Harrington RA, **Lincoff AM**, Simoons ML, Deckers JW, Califf RM, Topol EJ for the PURSUIT Investigators. Empiric use of platelet glycoprotein IIb/IIIa receptor blockade for patients with acute coronary syndromes who did not undergo coronary revascularization. *Circulation* in press.
173. Thel MC, Davidson CJ, Aguirre FV, Peck SL, **Lincoff AM**, Topol EJ, Califf RM, Tcheng JE, for the IMPACT-II Investigators. Predictors of contrast nephropathy after percutaneous coronary interventions: insights from IMPACT-II. *Journal of the American College of Cardiology*, submitted.
174. Roe MT, Lauer MA, Harrington RA, Granger CB, Houghtaling PL, **Lincoff AM**, Cokkinos D, Stepinska J, Keltai M, Pfisterer M, Kleiman NS, Armstrong PW, Wilcox RG, Simoons ML, Deckers JW, Ardissino D, Betriu A, Califf RM, Topol EJ, for the GUSTO-IIb and PURSUIT Investigators. Contemporary global patterns of coronary angiography for non-ST-segment elevation acute coronary syndromes: results from the combined GUSTO-IIb and PURSUIT trials. *Journal of the American College of Cardiology*, submitted.
175. Roe MT, Booth J, **Lincoff AM**, Debowey DL, Ols ML, Ivanc TB, Stoner G, Cabot C, Anderson KM, Barnathan E, Topol EJ, Moliterno DJ for the EPILOG Investigators. Preprocedural angiographic risk assessment is not a reliable method of determining indications for abciximab during coronary intervention. *American Journal of Cardiology*, submitted.
176. Akkerhuis KM, **Lincoff AM**, Harrington RA, Boersma E, Borzak S, Mahaffey KW, Topol EJ, Califf RM, Simoons ML, Deckers JW, for the PURSUIT Investigators. Predictors of bleeding in patients with acute coronary syndromes without persistent ST-segment elevation treated with glycoprotein IIb/IIIa receptor inhibition: results of an international trial of 9461 patients. *Journal of the American College of Cardiology*, submitted.

Edited Books

1. **Lincoff AM** and Topol EJ, eds. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Medicine. Humana Press, Totowa, New Jersey, 1999.
2. Lauer MA and **Lincoff AM**. Acute Coronary Syndromes, [Section Editors]. In: Marso SP, Griffin BP, Topol EJ. Manual of Cardiovascular Medicine, Lippincott Williams & Wilkins, Philadelphia, PA, 2000.
3. **Lincoff AM**, ed. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Medicine, 2nd Edition. Humana Press, Totowa, New Jersey, 2003.
4. Askari A, **Lincoff AM**. Section I. Ischemic Heart Disease [Section Editors]. In: Griffin BP, Topol EJ, eds. Manual of Cardiovascular Medicine. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2004. p. 1-98.

Book Chapters, Symposia, and Reviews

1. **Lincoff AM**, Grossman IE, Blau GE. Separation system for recovery of ethylene and light products from a naphtha-pyrolysis gas stream: preliminary design and economic analysis. *CACHE Process Design Case Studies* 1983, Vol 1.
2. Sevick EM, Borovetz HS, **Lincoff AM**. Influence of random noise on parameter estimates derived from a mathematical model of the arterial uptake of lipoprotein molecules. *American Society of Mechanical Engineers (ASME) Biomechanics Symposium* 1985;151-4.
3. **Lincoff AM**, Ellis SG. Pre-procedural assessment of risk for ischemic complications during coronary angioplasty. *Choices in Cardiology* 1992;6:91-94.
4. **Lincoff AM**, Popma JJ. Support Devices. In: Bates ER ed., Thrombolysis and Adjunctive Therapy for Acute Myocardial Infarction, New York, Marcel Dekker, Inc., 1992, pp. 417-448.
5. **Lincoff AM**, Topol EJ. Abrupt Vessel Closure. In: Topol EJ ed. Textbook of Interventional Cardiology - Update 5, W. B. Saunders, Philadelphia, Pennsylvania, 1992.
6. Evans DJ, **Lincoff AM**, Topol EJ. Heparin, aspirin, and new agents for prevention of thrombotic complications in coronary interventions. *Cardio Intervention* 1992;2:12-22.
7. Brener SJ, **Lincoff AM**, Topol EJ. An update on coronary thrombolysis. *Hospital Medicine* 1993;29(12)11-25.
8. **Lincoff AM**, Topol EJ. Abrupt Vessel Closure. In: Topol EJ ed. Textbook of Interventional Cardiology, 2nd Edition W.B. Saunders, Philadelphia, Pennsylvania, 1994, pp. 207-230.
9. Zidar JP, **Lincoff AM**, Stack RS. Biodegradable Stents. In: Topol EJ ed. Textbook of Interventional Cardiology, 2nd Edition W.B. Saunders, Philadelphia, Pennsylvania, 1994, pp. 787-802.

10. **Lincoff AM.** Patients at high risk for ischemic complications. *Journal of Invasive Cardiology* 1994;6(Suppl A):13A-18A.
11. Silver MJ, **Lincoff AM**, Topol EJ. Thrombolytic therapy for acute myocardial infarction in women. A state of the art review. *Primary Cardiology* 1995;21:19-31.
12. Ohman EM, Harrington RA, **Lincoff AM**, Kitt M, Kleiman NS, Tchong JE. Early clinical experience with Integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. *European Heart Journal* 1995;16:50-55.
13. **Lincoff AM**, Topol EJ. Thrombolytic Therapy. In: Fuster VJ, Ross R, Topol EJ eds. Atherosclerosis and Coronary Artery Disease Raven Press, New York, New York, 1996; pp 955-977.
14. Gottsauner-Wolf M, Moliterno DJ, **Lincoff AM**, Topol EJ. Restenosis - an open file. *Clinical Cardiology* 1996;19:347-356.
15. **Lincoff AM.** Heparin and control of bleeding complications during platelet glycoprotein IIb/IIIa receptor antagonist therapy during percutaneous coronary revascularization. *Journal of Invasive Cardiology* 1996;8:15B-20B.
16. **Lincoff AM.** Antiplatelet agents in acute myocardial infarction. In: Rose BD ed. UpToDate™ BRD Inc., Wellesley, MA. (CD-ROM).
17. **Lincoff AM.** Heparin therapy in acute myocardial infarction. In: Rose BD ed. UpToDate™ BRD Inc., Wellesley, MA. (CD-ROM).
18. **Lincoff AM.** Direct antithrombin therapy in acute myocardial infarction. In: Rose BD ed. UpToDate™ BRD Inc., Wellesley, MA. (CD-ROM).
19. **Lincoff AM.** Clinical trials for prevention of restenosis. *Chonnam Journal of Medical Sciences* 1996;9:111-121.
20. **Lincoff AM**, Topol EJ. Interventional Catheterization Techniques. In: Braunwald E ed. Heart Disease, Fifth Edition W.B. Saunders, Philadelphia, Pennsylvania, 1997; pp 1366-1391.
21. Eccleston DS, **Lincoff AM.** Catheter-based drug delivery for restenosis. *Advanced Drug Delivery Reviews* 1997;24:31-43.
22. Guetta V, **Lincoff AM.** EPIC, IMPACT II, and EPILOG. Platelet GP IIb/IIIa inhibition for prevention of ischemic complications and restenosis of percutaneous coronary interventions. In: Serruys PW and Holmes D eds. Current Review of Interventional Cardiology, 3rd Edition, Current Medicine, Philadelphia, PA, 1997; pp 141-149.
23. Guzman LA, **Lincoff AM.** Thrombolytic therapy: the treatment of choice in acute myocardial infarction. *Journal of Thrombosis and Thrombolysis* 1997;4:337-343.
24. Steinhubl SR, **Lincoff AM.** Antithrombotic therapy with intracoronary stenting. *Heart* 1997;78:21-23.

25. **Lincoff AM**, Weinberger J. Local drug delivery and endovascular radiation. In: Topol EJ ed. Textbook of Cardiovascular Medicine, Lippincott-Raven Publishers, Philadelphia, PA, 1998;pp 2433-2452.
26. Steinhubl SR, **Lincoff AM**. Antiplatelet drugs in unstable angina. In: Turpie AGG ed. Unstable Angina, Current Medical Literature Ltd, London, England, 1998, pp.12-30.
27. Lauer MA, **Lincoff AM**. Parenteral direct antithrombins. In: Uprichard ACG and Gallagher KP eds. Handbook of Experimental Pharmacology, Springer-Verlag, Shrewsbury, UK, 1998, Vol 132, pp 331-352.
28. Guetta V, **Lincoff AM**. Clinical experience with abciximab during coronary revascularization: an overview. *BioDrugs* 1998;10:27-39.
29. **Lincoff AM**. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. *American Journal of Cardiology* 1998;82:36P-42P.
30. **Lincoff AM**, Topol EJ. Abrupt vessel closure. In: Topol EJ ed. Textbook of Interventional Cardiology 3rd Edition W.B. Saunders, Philadelphia, Pennsylvania, 1999, pp. 163-187.
31. Kleiman NS, **Lincoff AM**, Ohman EM, Harrington RA. GP IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. *American Heart Journal*, 1998;136:S32-S42.
32. **Lincoff AM**. Abciximab in percutaneous coronary intervention: EPIC, EPILOG, and EPISTENT trials. In: **Lincoff AM** and Topol EJ, eds. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Medicine, Humana Press, Totowa, New Jersey, 1999, pp. 93-113.
33. **Lincoff AM**, Topol EJ. Overview of the GP IIb/IIIa interventional trials. In: **Lincoff AM** and Topol EJ, eds. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Medicine, Humana Press, Totowa, New Jersey, 1999, pp. 169-197.
34. Park S-H, **Lincoff AM**. Antiinflammatory stent coatings: dexamethason and related compounds. In: Serruys P, ed. Seminars in Interventional Cardiology, 1998;3:191-195.
35. **Lincoff AM**, Korngold S. An overview of platelet GP IIb/IIIa receptor antagonist trials. *European Heart Journal* 1999;1(Suppl E):E18-E26.
36. Steinhubl ST, **Lincoff AM**. Long-term antithrombotic therapy in acute coronary syndromes: where do we go from here. *Acute Coronary Syndromes* 1999;2:34-41.
37. **Lincoff AM**. Platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. In: Ellis SG ed. Strategic Approaches in Coronary Intervention 2nd Edition, Williams and Wilkins, Philadelphia, PA, 2000; pp.550-563.
38. Roe MT, **Lincoff AM**. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. *Cleveland Clinic Journal of Medicine* 2000;67:131-140.

39. **Lincoff AM.** Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial. *American Heart Journal* 2000;139:S46-S52.
40. Campbell KR, Ohman EM, Cantor W, **Lincoff AM.** The use of glycoprotein IIb/IIIa inhibition therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. *American Journal of Cardiology* 2000;85:32C-38C.
41. **Lincoff AM.** GUSTO IV: expanding therapeutic options in acute coronary syndromes. *American Heart Journal* 2000;140:S103-114.
42. L'Allier PL, **Lincoff AM.** Early invasive versus early conservative strategies for acute coronary syndromes. In: Topol EJ ed. Acute Coronary Syndromes 2nd Edition, Marcel Dekker, Inc., New York, 2001; pp 391-418.
43. Chan AW, Chew DP, **Lincoff AM.** Update on pharmacology for restenosis. *Current Interventional Cardiology Reports* 2001;3:149-155.
44. **Lincoff AM.** Combination therapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa receptor inhibitors: SPEEDing into GUSTO V. *Journal of Invasive Cardiology.*, 2001;13:16A-8A.
45. L'Allier PL, **Lincoff AM.** Platelet glycoprotein IIb/IIIa inhibitors combined with fibrinolytic agents to treat acute myocardial infarction. *Journal of Thrombosis and Thrombolysis* 2001;11:83-91.
46. **Lincoff AM.** Thrombocytopenia after percutaneous coronary intervention." *ACC Spotlight Series:ACCIS 2001.* Boston: Physician Education; 2001. (CD-ROM)
47. **Lincoff AM.** Anticoagulant and antiplatelet drugs. *Catheterization and Cardiovascular Intervention* 2001;54:514-520.
48. Chew DP, **Lincoff AM.** Adjunctive pharmacotherapy and coronary intervention. In: Grech and Ramsdale, eds. Practical Interventional Cardiology 2nd Edition, Martin Dunitz Publishers, London, England, 2002; pp 207-224.
49. Weinberger J, **Lincoff AM,** Popma JJ. Radiation, Emboli Protection, and Therapeutic Angiogenesis. In: Topol EJ ed. Textbook of Cardiovascular Medicine 2nd Edition, Lippincott-Raven Publishers, Philadelphia, PA, 2002;pp 1677-1694.
50. Gum PA, **Lincoff AM.** Direct thrombin inhibitors in acute coronary syndromes and percutaneous coronary intervention. *Acute Coronary Syndromes* 2002;4:106-112.
51. Jneid H, Rimmerman CM, **Lincoff AM.** Acute Coronary Syndromes. In: Stoller JK, Ahmad M, Longworth DL, eds. Intensive Review of Internal Medicine 3rd Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2002;pp 860-873.
52. Askari AT, **Lincoff AM.** GUSTO V: Combination drug treatment of acute myocardial infarction. *Cleveland Clinic Journal of Medicine* 2002;69:554-560.

53. **Lincoff AM.** Targeting the use of platelet IIb/IIIa inhibitors: treatment of acute myocardial infarction. *Reviews in Cardiovascular Medicine* 2002;3(Suppl 1):S13-S19.
54. Steinhubl SR, **Lincoff AM.** Antiplatelet drugs in unstable angina. In: Turpie AGG ed. Unstable Angina, Current Medical Literature Ltd, London, England, 2002, pp.11-33.
55. **Lincoff AM.** The GUSTO V clinical trial. *Journal of Invasive Cardiology* 2002;14:21A-30A.
56. **Lincoff AM.** Management of acute coronary syndromes with emphasis on new information for the treatment of ST-segment elevation acute myocardial infarction. *Journal of Invasive Cardiology* 2002;14:1A-2A.
57. **Lincoff AM.** Abrupt vessel closure. In: Topol EJ, Ed. Textbook of Interventional Cardiology, 4th Edition. Saunders, Philadelphia, PA, 2002;pp 267-284.
58. **Lincoff AM, Ellis SG.** Mechanical approaches to percutaneous coronary intervention. In: Antmann EM, ed. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. 2nd Edition, W.B. Saunders and Company, Philadelphia, PA 2002;pp 865-884.
59. Gum PA, **Lincoff AM.** Abciximab and atherosclerotic heart disease: Use in percutaneous coronary intervention, acute coronary syndromes, and acute myocardial infarction. *International Journal of Clinical Practice* 2003;57:43-48.
60. Bhatt D, **Lincoff AM.** Abciximab. In: Sasahara A and Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis, Marcel Dekker, Inc, New York, NY, 2003;pp 349-369.
61. **Lincoff AM.** Abciximab in percutaneous coronary intervention: EPIC, EPILOG, and EPISTENT trials. In: **Lincoff AM**, ed. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Medicine. 2nd Edition, Humana Press, Totowa, New Jersey, 2003, pp.105-124.
62. **Lincoff AM, Topol EJ.** Overview of the GP IIb/IIIa interventional trials. In: **Lincoff AM**, ed. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Medicine. 2nd Edition, Humana Press, Totowa, New Jersey, 2003, pp. 167-199.
63. **Lincoff AM, Bittl JA, Harrinton R, Seybert AL, Coons JC.** Bivalirudin combined with provisional GP IIb/IIIa blockade is safer than heparin plus planned GP IIb/IIIa blockade during percutaneous coronary intervention. *Evidence-Based Cardiovascular Medicine* 2003;7:173-175.
64. Topol E, **Lincoff M**, Kereiakes D. Abciximab reduces long-term mortality following percutaneous, coronary intervention. *Evidence-Based Cardiovascular Medicine* 2003;7:21-23.
65. **Lincoff AM.** Direct thrombin inhibitors for non-ST segment elevation acute coronary syndromes: what, when, and where? *American Heart Journal* 2003;146:S23-S30.
66. Exaire JE, **Lincoff AM.** Should GP IIb/IIIa inhibitors be used during all PCIs? *Journal of Thrombosis and Haemostasis* 2004;2:7-9.

67. Marso SP, **Lincoff AM**. The EPISTENT Diabetic Substudy. In: Braunwald E, ed. Harrison's Online, McGraw Hill, New York, NY, http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/ex_editorials/ed12340_p01.html.
68. **Lincoff AM**. Glycoprotein IIb/IIIa inhibitors. *Journal of Invasive Cardiology* 2004;16(suppl):11S-16S.
69. Dauterman KW, **Lincoff AM**. PCI Trials: Angioplasty, stenting, IVUS-guidance, and pharmacologic treatment to prevent acute complications and restenosis. In: Roffi M, Meier B, Topol EJ (eds): A Comprehensive Handheld-Based Approach to Cardiovascular Medicine. Handheldmed, Inc., Little Rock, AR, USA, 2004.
70. Maroo A, **Lincoff AM**. Bivalirudin in PCI: Overview of the REPLACE-2 Trial. *Seminars in Thrombosis and Hemostasis* 2004;30:329-336.
71. Ellis BK, **Lincoff AM**. Hemostatic devices. In: Aviles RJ, ed. Introductory Guide to Cardiac Catheterization. Philadelphia: Lippincott Williams & Wilkins, 2004. Chapter 8. p. 125-134.
72. Gurm HS, **Lincoff AM**. Post-cath. In: Aviles RJ, ed. Introductory Guide to Cardiac Catheterization. Philadelphia: Lippincott Williams & Wilkins, 2004. Chapter 9. p. 135-140.
73. Tamberella MR, III, **Lincoff AM**. High-risk coronary angiography. In: Aviles RJ, ed. Introductory Guide to Cardiac Catheterization. Philadelphia: Lippincott Williams & Wilkins, 2004. Chapter 7. p. 111-124.
74. L'Allier P, **Lincoff AM**. Early invasive vs conservative strategies for ACS management. In: Topol EJ, ed. Acute Coronary Syndromes, 3rd Edition, Marcel Dekker, New York, NY, 2005;pp.351-368.
75. Zidar F, **Lincoff AM**. Thrombolytic Therapy. In: Fuster VJ, Topol EJ, Nabel EG eds. Atherothrombosis and Coronary Artery Disease, 2nd Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2005;pp 987-1016.
76. Jneid H, Rimmerman CM, **Lincoff AM**. Acute Coronary Syndromes. In: Stoller JK, Michota FA, Mandell BF, eds. The Cleveland Clinic Intensive Review of Internal Medicine 4th Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2005;pp 838-850.
77. Jefferson BK, Chiu JH, Tuzcu EM, **Lincoff AM**. Bivalirudin use in primary percutaneous coronary intervention in a patient at high risk for thrombohemorrhagic complications. *Journal of Invasive Cardiology* 2004;6(9-supplement).
78. Chen MS, **Lincoff AM**. Direct thrombin inhibitors. *Current Cardiology Reports* 2005;7:255-259.
79. Zhou Z, Wang K, **Lincoff AM**. Dexamethasone eluting stent. In: Camenzind E and De Scheerder I, eds. Handbook of Local Drug Delivery, Martin Dunitz Publishers, London, England, in press.

Abstracts (Presented)

1. Borovetz HS, Inskip WH, **Lincoff AM**, Hardesty RL. Mathematical model of extravascular pulmonary diffusion: application to data of multiple indicator dilution. *Federation Proceedings* 1982;41:1673. Presented at the Federation of American Societies for Experimental Biology Annual Meeting, 1982.
2. **Lincoff AM**, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure following coronary angioplasty: clinical, angiographic, and therapeutic profile. *Circulation* 1990;82:III-189. Presented at the American Heart Association Scientific Sessions, 1990.
3. **Lincoff AM**, Chapekis AT, George BS, Muller DWM, Topol EJ, Ellis SG. Disparity between immediate procedural and in-hospital clinical outcomes after intracoronary stenting for abrupt vessel closure. *Circulation* 1991;84:II-588. Presented at the American Heart Association Scientific Sessions, 1991.
4. **Lincoff AM**, Muller DWM, Candela RJ, Zimmerman C, Chapekis AT, Ellis SG. Comparative study of long-term outcome following intracoronary stenting vs conventional therapy for abrupt vessel closure during coronary angioplasty. *Circulation* 1991;84:II-518. Poster presented at the American Heart Association Scientific Sessions, 1991.
5. **Lincoff AM**, Muller DWM, Ellis SG, Hacker JA, Topol EJ. Can restenosis after coronary stenting be diagnosed by stress thallium imaging? *Journal of the American College of Cardiology*, 1992;19:110A. Poster presented at the American College of Cardiology Annual Scientific Session, 1992.
6. **Lincoff AM**, Califf RM, Sigmon KN, Lee KL, Topol EJ. Women and thrombolysis: therapy and outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. *European Heart Journal*, 1992;13(suppl):305. Presented at the European Society of Cardiology Congress, 1992.
7. **Lincoff AM**, Schwartz RS, van der Giessen WJ, van Beusekom HMM, Serruys PW, Holmes DR, Ellis, SG, Topol EJ. Biodegradable polymers can evoke a unique inflammatory response when implanted in the coronary artery. *Circulation* 1992;86:I-801. Presented at the American Heart Association Scientific Sessions, 1992.
8. **Lincoff AM**, Guzman LA, Casale PN, Ellis SG, Whitlow PL. Impact of atherectomy devices on the management of saphenous vein graft lesions with associated thrombus. *Circulation* 1992;86:I-779. Presented at the American Heart Association Scientific Sessions, 1992.
9. **Lincoff AM**, Ellis SG, Galeana A, Sigmon KN, Lee KL, Rosenschein U. Is a coronary artery with TIMI grade 2 flow "patent"? Outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trial. *Circulation* 1992;86:I-268. Presented at the American Heart Association Scientific Sessions, 1992.

10. **Lincoff AM**, van der Giessen WJ, Schwartz RS, van Beusekom HMM, Serruys PW, Holmes DR, Ellis SG, Topol EJ. Biodegradable and biostable polymers may both cause vigorous inflammatory responses when implanted in the porcine coronary artery. *Journal of the American College of Cardiology* 1993;21:179A. Presented at the American College of Cardiology Annual Scientific Sessions, 1993.
11. **Lincoff AM**, Cowley MJ, DeLuca SA, DeBottis D, Whitlow PL. Is "late loss" of "early gain" in coronary luminal diameter different following rotational atherectomy and balloon angioplasty? A paired quantitative angiographic study. *Journal of the American College of Cardiology* 1993;21:444A. Poster presented at the American College of Cardiology Annual Scientific Sessions, 1993.
12. **Lincoff AM**, Califf RM, Berdan LG, Keeler GP, Topol EJ. Procedural indicators of in-hospital myocardial infarction are different between coronary atherectomy and angioplasty: insights from the CAVEAT trial. *European Heart Journal* 1993;14(Suppl):79. Presented at the European Society of Cardiology Congress, 1993.
13. **Lincoff AM**, Furst JG, Lee P. Local delivery of dexamethasone by an eluting stent attenuates the adverse response to biodegradable polymer in the porcine coronary artery. *Circulation* 1993;88:I-655. Poster presented at the American Heart Association Scientific Sessions, 1993.
14. **Lincoff AM**, Keeler GP, Debowey D, Topol EJ. Is clinical site variability an important determinant of outcome following percutaneous revascularization with new technology? Insights from CAVEAT. *Circulation* 1993;88:I-653. Poster presented at the American Heart Association Scientific Sessions, 1993.
15. **Lincoff AM**, Ellis SG, Leya F, Masden RR, Raymond RE, Keeler GP. Are clinical and angiographic correlates of success the same during directional coronary atherectomy and balloon angioplasty? The CAVEAT experience. *Circulation* 1993;88:I-601. Presented at the American Heart Association Scientific Sessions, 1993.
16. **Lincoff AM**, Furst JG, Ellis SG, Topol EJ. Sustained local drug delivery by a novel intravascular eluting stent to prevent restenosis in the porcine coronary artery. *Journal of the American College of Cardiology* 1994:18A. Poster presented at the American College of Cardiology Annual Scientific Sessions, 1994.
17. **Lincoff AM**, Furst JG, Penn MS, Lee P, MacIsaac AI, Chisolm GM, Topol EJ, Ellis SG. Efficiency of solute transfer by a microporous balloon catheter in the porcine coronary model of arterial injury. *Journal of the American College of Cardiology* 1994:18A. Poster presented at the American College of Cardiology Annual Scientific Sessions, 1994.
18. **Lincoff AM**, Califf RM, Anderson K, Weisman HF, Topol EJ. Striking clinical benefit with platelet GP IIb/IIIa inhibition by c7E3 among patients with unstable angina: outcome in the EPIC trial. *Circulation* 1994;90:I-21. Presented at the American Heart Association Scientific Sessions, 1994.

19. **Lincoff AM**, Keeler GP, Berdan LG, Debowey D, Topol EJ. "Worst view" angiographic analysis in CAVEAT provided a "worst case" scenario of restenosis rates and vessel luminal diameters. *Circulation* 1994;90:I-60. Poster presented at the American Heart Association Scientific Sessions, 1994.
20. **Lincoff AM**, Tcheng JH, Bass TA, Popma JJ, Teirstein PS, Kleiman NS, Weisman HF, Musco MH, Cabot CF, Berdan LG, Califf RM, Topol EJ. A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with the platelet GP IIb/IIIa receptor antibody 7E3 during percutaneous coronary revascularization. *Journal of the American College of Cardiology* 1995;25:80A. Presented at the American College of Cardiology Annual Scientific Sessions, 1995.
21. **Lincoff AM**, Califf RM, Rutsch W, Stebbins A, Topol EJ. Thrombolytic therapy during the "golden first hour" in GUSTO. *Journal of the American College of Cardiology* 1995;25:87A. Presented at the American College of Cardiology Annual Scientific Sessions, 1995.
22. **Lincoff AM**, Topol EJ, Califf RM, Weisman HF, Wilderman NM, Ellis SG. Influence of platelet GP IIb/IIIa receptor inhibition with c7E3 on the sequelae of dissection during percutaneous coronary revascularization. *Journal of the American College of Cardiology* 1995;25:390A. Poster presented at the American College of Cardiology Annual Scientific Sessions, 1995.
23. **Lincoff AM**, Tcheng JE, Ellis SG, Moliterno DJ, Kitt MM, Debowey D, Topol EJ, for the IMPACT II Investigators. Randomized trial of platelet glycoprotein IIb/IIIa inhibition with Integrelin for prevention of restenosis following coronary intervention: the IMPACT II Angiographic Substudy. *Circulation* 1995;92:I-607. Poster presented at the American Heart Association Scientific Sessions, 1995.
24. **Lincoff AM**, Gottsauner-Wolf M, Jang Y, Grant G, Cohen JC, Penn MS, Chisolm GM, Kaplan AV, Ellis SG. Assessment of local drug delivery by the InfusaSleeve following coronary artery injury. *Circulation* 1995;92:I-671. Presented at the American Heart Association Scientific Sessions, 1995.
25. **Lincoff AM**, Tcheng JE, Miller DP, Booth JE, Montague EA, Topol EJ. Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 Fab (abciximab) linked to reduction in bleeding complications: outcome in the EPILOG and EPIC trials. *Circulation* 1996;94:I-375. Poster presented at the American Heart Association Scientific Sessions, 1996.
26. **Lincoff AM**, Tcheng JE, Califf RM, Cabot CF, Miller DP, Booth JE, Montague EA, Anderson KM, Topol EJ. Abciximab (c7E3 Fab, ReoPro) with reduced heparin dosing during coronary intervention: final results of the EPILOG trial. *Journal of the American College of Cardiology* 1997;29:187A. Presented at the American College of Cardiology Annual Scientific Sessions, 1997.
27. **Lincoff AM**, Mark DB, Califf RM, Tcheng JE, Ellis SG, Davidson-Ray L, Anderson KM, Stoner GL, Topol EJ. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade during coronary intervention in the EPILOG trial. *Journal of the American College of Cardiology* 1997;29:240A. Presented at the American College of Cardiology Annual Scientific Sessions, 1997.

28. **Lincoff AM, Tcheng JE, Anderson KM, Cabot CF.** Durable inhibition of ischemic complications by abciximab during percutaneous coronary revascularization: one year results of the EPILOG trial. *Circulation* 1997;96:I-162. Moderated poster presented at the American Heart Association Scientific Sessions, 1997.
29. **Lincoff AM, Harrington RA, Califf RM, Berdan LG, Kitt MM, Weatherly BD, Kleiman NS, Topol EJ.** Clinical efficacy of Integrilin in unstable angina is accompanied by a modest increase in hemorrhagic risk: the PURSUIT Trial. *Journal of the American College of Cardiology* 1998;31:185A. Presented at the American College of Cardiology Annual Scientific Sessions, 1998.
30. **Lincoff AM, Booth JE, Godfrey NK, Kramer J, Kelly T, Topol EJ.** Periprocedural myocardial infarctions prevented by IIb-IIIa blockade are clinically and angiographically manifest and large: the EPISTENT experience. *Circulation* 1998;98:I-766. Presented at the American Heart Association Scientific Sessions, 1998.
31. **Lincoff AM, Tcheng JE, Califf RM, Cabot CF, Booth JE, Godfrey NK, Topol EJ.** The EPISTENT trial at 6 months: relative and combined effects of abciximab and stenting on reduction of acute ischemic events and late revascularization. *Circulation* 1998;98:I-767. Presented at the American Heart Association Scientific Sessions, 1998.
32. **Lincoff AM, Moliterno DJ, Ellis SG, Debowey D, Cabot CF, Booth JE, Godfrey NK, Topol EJ.** Six month angiographic outcome with abciximab and stents: the EPISTENT Angiographic Substudy. *Circulation* 1998;98:I-768. Presented at the American Heart Association Scientific Sessions, 1998.
33. **Lincoff AM, Tcheng JE, Cabot CF, Califf RM, Booth JE, Sapp S, Topol EJ.** Marked benefit in diabetic patients treated with stent and abciximab combination: 6 month outcome of the EPISTENT trial. *Journal of the American College of Cardiology* 1999;33:34A. Presented at the American College of Cardiology Annual Scientific Sessions, 1999.
34. **Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Topol EJ.** Abciximab suppresses the rise in plasma levels of inflammatory markers following PTCA. *Circulation* 2000;102:II-330. Presented at the American Heart Association Scientific Sessions, 2000.
35. **Lincoff AM, Bittl JA, Kleiman NS, Kereiakes DJ, Harrington RA, Sarembock IJ, Jackman D, Mehta S, Maierson EF, Chew DP, Topol EJ for the REPLACE Investigators.** The REPLACE 1 Trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade. *Journal of the American College of Cardiology* 2002;39:16A. Poster presented at the American College of Cardiology Annual Scientific Sessions, 2002.

Abstracts (Other)

1. Borovetz HS, **Lincoff AM**, Inskeep WH. Role of convective dispersion in mathematical modelling of pulmonary capillary transport. *Federation Proceedings* 1983;42:580.

2. Borovetz HS, **Lincoff AM**, Inskip WH. One-dimensional versus two-dimensional models of pulmonary capillary transport: application to data of multiple indicator dilution. *Microvascular Research* 1983;25:226.
3. **Lincoff AM**, Borovetz HS. Mathematical model of lipoprotein transport across the arterial wall. *Microvascular Research* 1984;27:253.
4. Borovetz HS, Sevick EM, **Lincoff AM**. Parameter sensitivity analysis: application to model predictions of transport parameters governing arterial wall uptake of 14-C cholesterol. *Microvascular Research* 1986;31:156.
5. Neumann SJ, Sevick EM, **Lincoff AM**, Borovetz HS. Effect of random noise contamination and smoothing on regression accuracy of an arterial wall mass transport model. *Federation Proceedings* 1987;46:1391.
6. Cleary RM, **Lincoff AM**, Popma JJ, Hacker JA, Ellis SG, Topol EJ, Bates ER. Increased risk for abrupt closure during elective PTCA in the post-myocardial infarction period. *Journal of the American College of Cardiology* 1991;17:267A.
7. Ellis SG, Cowley MJ, Vandormael M, **Lincoff AM**, DiSciascio G, Dean LS, Topol EJ. Coronary revascularization in 1986-87 and 1991 - Dramatically improved acute phase results using percutaneous technologies. *Circulation* 1992;86:I-372.
8. Ellis SG, Arnold AZ, Raymond RE, Eigler JL, Sanborn TA, Bittl JA, **Lincoff AM**, Mooney MR, Tchong JE, Topol EJ. Increased coronary perforation in the new device era: incidence, classification, management, and outcome. *Circulation* 1992;86:I-787.
9. De Franco AD, Tuzcu EM, Abdelmeguid A, **Lincoff AM**, Brown D, Bernardi M, Ellis SG, Whitlow PL, Sutton JM, Casale PN, Raymond RE, Topol EJ, Nissen SE. Intravascular ultrasound assessment of PTCA results: insights into the mechanisms of balloon angioplasty. *Journal of the American College of Cardiology* 1993;21:485A.
10. van der Giessen WJ, **Lincoff AM**, Schwartz RS, van Beusekom HMM, Serruys PW, Holmes DR, Ellis SG, Topol EJ. Biocompatibility of synthetic biodegradable and biostable polymers after implantation in the porcine coronary artery. *European Heart Journal* 1993;14(Suppl)352.
11. Ellis SG, Yakubov S, **Lincoff AM**, Tuzcu M, George BS. When to stent for threatened and true closure after coronary intervention - analysis of 343 patients in the immediate pre-stent and later stent era. *Circulation* 1993;88:I-585.
12. Ellis SG, Bittl JA, **Lincoff AM**, Adelman B, Wolfe MW, Whitlow PL, Topol EJ. Consumer "scorecard" for interventional cardiologists. *Journal of the American College of Cardiology* 1994:59A.
13. Ellis SG, **Lincoff AM**, George BS, Kereiakes DJ, Krucoff MW, Ohman M. Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for acute myocardial infarction. *Journal of the American College of Cardiology* 1994:244A.

14. Berkalp B, Nissen SE, De Franco AC, Moliterno DJ, Franco I, Raymond RE, Sutton J, **Lincoff AM**, Guyer S, Tuzcu EM. Intravascular ultrasound demonstrates marked differences in surface and lumen shape following interventional devices. *Circulation*;1994;90:I-58.
15. Harrington RA, Gerstenblith G, Kleiman NS, **Lincoff AM**, Schulman S, Goldschmidt P, Joseph D, Sigmon KN, Parker J, Marchant K, Kitt M, Topol EJ, Califf RM. Profound, sustained, and reversible platelet inhibition following administration of a glycoprotein IIb/IIIa inhibitor with and without heparin in patients with unstable angina. *Circulation* 1994;90:I-232.
16. Schulman SP, Gottdiener P, Navetta FI, Chandra NC, Harrington RA, **Lincoff AM**, Ferguson JJ, Wolfe CL, Nygaard TW, Bahr RD, Kitt MM, Gerstenblith G. Rebound ischemia does not occur in unstable angina patients withdrawn from Integrelin - a fibrinogen receptor antagonist. *Circulation* 1994;90:I-372.
17. Jang Y, Guzman LA, **Lincoff AM**, Gottsauner-Wolf M, Forudi F, Hart CE, Ellis SG, Topol EJ. Extrinsic coagulation pathway inhibition using inactivated factor VIIa limits restenosis in the rabbit atherosclerotic model. *Journal of the American College of Cardiology*, 1995;25:9A.
18. Eccleston DS, **Lincoff AM**, Furst JG. Administration of colchicine using a novel prolonged delivery stent produces a marked local biological effect within the porcine coronary artery. *Circulation* 1995;92:I-87.
19. Tcheng JE, **Lincoff AM**, Sigmon KN, Kitt MM, Califf RM, Topol EJ for the IMPACT II Investigators. Platelet glycoprotein IIb/IIIa inhibition with Integrelin during percutaneous coronary intervention: the IMPACT II Trial. *Circulation* 1995;92:I-543.
20. Guzman LA, Labhassetwar V, Song C, Jang Y, **Lincoff AM**, Levy R. Single intraluminal infusion of biodegradable polymeric nanoparticles matrixed with dexamethasone decreases neointimal formation after vascular injury. *Circulation* 1995;92:I-293.
21. Harrington RA, Ohman EM, Sigmon KN, Kleiman NS, Schulman SP, Kottke-Marchant K, **Lincoff AM**, Joseph D, Parker J, Kitt MM, Topol EJ, Califf RM. Intensity of inhibition of the platelet glycoprotein IIb/IIIa receptor differs among disease states. *Circulation* 1995;92:I-489.
22. Eccleston DS, Furst J, Labhassetwar V, Levy RJ, **Lincoff AM**. Local delivery of polymeric nanospheres containing heparin reduces platelet deposition in the porcine balloon injury model. *Circulation* 1995;92:I-670.
23. Bergelson GA, Davidson CJ, Hafley G, Ivanhoe RJ, Ferguson JJ, Tardiff BE, Mahaffey KW, **Lincoff AM**, Tcheng JE, Califf RM. Predictors of abrupt closure and consequences of emergency endpoints in the IMPACT II trial. *Journal of the American College of Cardiology* 1996;27:83A.
24. Aguirre FV, Ferguson JJ, Blankenship JC, Pieper K, Taylor MA, Harrington RA, Rund MM, Caracciolo EQ, Donohue TJ, Califf RM, **Lincoff AM**, Tcheng JE, Topol EJ. Association of pre-intervention activated clotting times and clinical outcomes following percutaneous coronary revascularization. Results from the IMPACT II trial. *Journal of the American College of Cardiology* 1996;27:83A.

25. Tuzcu EM, Ziada KM, DeFranco AC, Magyar WA, Crowe TD, **Lincoff AM**, Sutton JM, Simpfendorfer D, Nissen SE. Effect of coronary risk factors on plaque morphology: intravascular ultrasound evidence of differing patterns. *Journal of the American College of Cardiology* 1996;27:40A.
26. Tardiff BE, Califf RM, Tchong JE, **Lincoff AM**, Sigmon KN, Harrington RA, Mahaffey KW, Teirstein P, Heinsimer J, Topol EJ for the IMPACT II Investigators. Post-intervention cardiac enzyme elevations: prognostic significance in IMPACT II. *Journal of the American College of Cardiology* 1996;27:83A.
27. Horrigan MCG, Tchong JE, Califf RM, Kitt M, Lorenz T, Sigmon K, **Lincoff AM**, Topol EJ for the IMPACT II Investigators. Maximal benefit of Integrelin platelet IIb/IIIa blockade 6-24 hours after therapy: results of the IMPACT II trial. *Journal of the American College of Cardiology* 1996;27:55A.
28. Teirstein PS, Yakubov SJ, Thel MC, Wildermann N, Kereiakes DJ, Popma JJ, **Lincoff AM**, Tchong JE, Califf RM, Topol EJ. Platelet IIb/IIIa blockade with Integrelin: atherectomy patients. *Journal of the American College of Cardiology* 1996;27:334A.
29. DeFranco AC, Tuzcu EM, Ziada KM, Shah N, Babu S, **Lincoff AM**, Raymond R, Whitlow PL, Ellis SG, Nissen SE. High-pressure inflations do not insure "adequate" stent deployment: evidence from intravascular ultrasound. *Journal of the American College of Cardiology* 1996;27:305A.
30. Zidar JP, Kruse KR, Thel MC, Kereiakes D, Muhlstein JB, Davidson CJ, Teirstein PS, Tenaglia A, Yakubov SJ, Popma JJ, Tanguay JF, Kitt MM, Lorenz TJ, Tchong JE, **Lincoff AM**, Califf RM, Topol EJ. Integrelin for emergency coronary artery stenting. *Journal of the American College of Cardiology* 1996;27:138A.
31. Ward SR, **Lincoff AM**, Miller DP, Booth JE, Montague EA, Tchong J, Topol EJ. Clinical outcome is improved at 30 days regardless of pre-treatment clinical and angiographic risk in patients receiving abciximab for angioplasty: results from the EPILOG study. *Circulation* 1996;94:I-198.
32. Aguirre FV, Talley DJ, Ferguson JJ, Tchong J, Kleiman NS, Montague EA, Booth JE, **Lincoff AM**. Efficacy of abciximab, despite patient weight, using lower heparin dosing during percutaneous coronary interventions. *Circulation* 1996;94:I-198.
33. Ghaffari S, Kereiakes DJ, Kelly T, Tchong JE, Timmis GC, Miller DP, **Lincoff AM**. Platelet GP IIb/IIIa receptor blockade reduces ischemic complications in patients undergoing directional coronary atherectomy. *Circulation* 1996;94:I-198.
34. Le Breton H, Rabbani R, Plow EF, Mousa S, **Lincoff AM**, Forudi F, Topol EJ. The role of integrins $\alpha_{IIb}\beta_3$ (glycoprotein IIb/IIIa) and $\alpha_v\beta_3$ (the vitronectin receptor) in a guinea pig model of restenosis. *Circulation* 1996;94:I-517.
35. Belli G, Eccleston DS, Horrigan MC, Furst JG, **Lincoff AM**, Topol EJ. Locally delivered vascular endothelial growth factor (VEGF) does not inhibit neointimal proliferation in the porcine restenosis model. *Journal of the American College of Cardiology* 1997;29:52A.

36. Tardiff BE, Tcheng JE, Peck S, **Lincoff AM**, Harrington RA, Califf RM, Topol EJ for the IMPACT-II Investigators. Bleeding with coronary artery bypass surgery (CABG) in patients treated with a glycoprotein IIb/IIIa inhibitor. *Journal of the American College of Cardiology* 1997;29:141A.
37. Tcheng JE, Anderson K, Tardiff BE, Cabot CF, **Lincoff AM**, Califf RM, Topol EJ. Reducing the risk of percutaneous intervention after coronary bypass surgery: beneficial effects of abciximab treatment. *Journal of the American College of Cardiology* 1997;29:187A.
38. Deckers J, Califf RM, Topol EJ, **Lincoff AM**, Tcheng JE, Simoons ML. Use of abciximab (ReoPro) is not associated with an increased risk of stroke: overview of three randomized trials. *Journal of the American College of Cardiology* 1997;29:241A.
39. Steinhubl SR, Belli G, Wu C-J, Yoon J, Furst J, Gallupi GR, Kaplan AV, Topol EJ, **Lincoff AM**. Local delivery of tissue factor pathway inhibitor (TFPI) to reduce neointimal proliferation in the porcine balloon injury model. *Journal of the American College of Cardiology* 1997;29:243A.
40. Tcheng JE, **Lincoff AM**, Miller DP, Booth JE, Rund MM, Cabot CF, Weisman HF, Califf RM, Topol EJ. Benefits of abciximab accrue in the full spectrum of coronary interventional patients: insights from the EPILOG trial. *Journal of the American College of Cardiology* 1997;29:276A.
41. Aquirre FV, Topol EJ, Leimberger J, Kleiman N, **Lincoff AM**, Donohue TJ, Califf RM. Incidence and clinical outcome of abrupt vessel closure among patients receiving abciximab during high-risk percutaneous coronary intervention: EPIC trial results. *Journal of the American College of Cardiology* 1997;29:394A.
42. Ellis SG, **Lincoff AM**, Tcheng JE, Miller DP, Booth JE, Califf RM, Topol EJ for the EPILOG Study Participants. Is there a differential benefit of ReoPro during PTCA for patients with certain lesion types? *Journal of the American College of Cardiology* 1997;29:395A.
43. Silver MJ, Smull DL, Forudi F, Bucknell KA, Topol EJ, **Lincoff AM**. Use of very late antigen-4 (VLA-4) integrin binding blockade with connecting segment-1 peptide in prevention of restenosis after balloon angioplasty in the rabbit atherosclerotic model. *Journal of the American College of Cardiology* 1997;29:419A.
44. Thel MC, Davidson CJ, Aquirre FV, Peck SL, Tcheng JE, **Lincoff AM**, Topol EJ, Califf RM for the IMPACT II Investigators. What predicts contrast nephropathy after coronary intervention? Insights from the IMPACT II trial. *Journal of the American College of Cardiology* 1997;29:500A.
45. Blankenship JC, Anderson KM, Demko SL, **Lincoff AM**, Tcheng JE, Cabot CF. In-lab angiographic complications during coronary intervention with abciximab vs placebo in the EPILOG trial. *Circulation* 1997;96:I-162.
46. Kereiakes DJ, **Lincoff AM**, Miller DP, Tcheng JE, Weisman HF, Topol EJ. Abciximab reduces risk of unplanned coronary stent deployment: EPILOG trial results. *Circulation* 1997;96:I-163.

47. Motwani, JG, Wu C-J, Guzman LA, Forudi, F, **Lincoff AM**. Neutral endopeptidase inhibition attenuates neointimal hyperplasia in balloon-injured rat carotid arteries. *Circulation* 1997;96:I-172.
48. Powers JB, Connolly TM, Yoon JH, Wu CJ, Forudi F, Haug MT, Marchant K, Brooks L, **Lincoff AM**. Prevention of neointimal hyperplasia with recombinant leech antiplatelet protein (rLAPP) via blockade of platelet adhesion. *Circulation* 1997;96:I-289.
49. Kleiman NS, **Lincoff AM**, Aguirre FV, Kereiakes DJ, Miller DP, Cabot CF, Andersen K, Topol EJ. Should diabetics treated with abciximab receive more heparin than non-diabetics? Findings of multicenter trial. *Circulation* 1997;96:I-386.
50. Montague EA, Booth JE, Miller DP, Malone KJ, Zovkic VE, Clemons PV, **Lincoff AM**, Topol EJ. Is there a need for independent endpoint review of ischemic events in cardiovascular trials? *Circulation* 1997;96:I-504.
51. Kereiakes DJ, **Lincoff AM**, Simoons ML, deBoer MJ, Tcheng JE, Vahanian A, Anderson KM, Weisman HF, Califf RM, Topol EJ. Complementarity of stenting and abciximab for percutaneous coronary intervention. *Journal of the American College of Cardiology* 1998;31:54A.
52. Kereiakes DJ, Berkowitz SD, Anderson K, Simoons M, Vahanian A, **Lincoff AM**, Tcheng JE, Weisman H, Califf RM, Topol EJ. Abciximab associated thrombocytopenia: evidence for a complex interaction with heparin. *Journal of the American College of Cardiology* 1998;31:55A.
53. Alexander JH, Harrington RH, Guerci A, Weatherley BD, Karsch KR, Califf RM, Topol EJ, **Lincoff AM**, Armstrong PW. Prior aspirin use potentiates the effect of GP IIb/IIIa inhibition in patients with non-ST elevation acute coronary syndromes. *Journal of the American College of Cardiology* 1998;31:93A.
54. Deckers JW, Harrington RA, **Lincoff AM**, Topol EJ, Califf RM, Berdan LG, Weatherly BD, Wilcox RG, Armstrong PW, Kitt MM, Simoons ML. Regional variation in outcomes as determined by investigators and clinical events committee in an international trial of eptifibatid in non-ST segment elevation acute coronary syndromes. *Journal of the American College of Cardiology* 1998;31:309A.
55. Miller JM, Godfrey N, Balog C, **Lincoff AM**, Topol EJ. Particular benefit of platelet GP IIb/IIIa blockade and full heparin in patients with peripheral vascular disease undergoing PTCA. *Journal of the American College of Cardiology* 1998;31:455A.
56. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, Rosenthal ML, Topol EJ, **Lincoff AM**. Diabetics and non-diabetics achieve similar levels of platelet inhibition with abciximab therapy during and following percutaneous revascularization. *European Heart Journal* 1998;19:238.
57. Raymond RE, **Lincoff AM**, Booth JE, Anderson KM, Miller DP, Tcheng JE, Simoons ML, Califf RM, Topol EJ. Coronary bypass surgery within 12 hours of administration remains safe despite an increased risk of perioperative bleeding. *European Heart Journal* 1998;19:238.

58. Bhatt DL, **Lincoff AM**, Kereiakes DJ, Tcheng JE, Godfrey N, Califf RM, Topol EJ. Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. *European Heart Journal* 1998;19:239.
59. Park S-H, Marso SP, Forudi F, **Lincoff AM**. Diabetes and the response to arterial injury. *Circulation* 1998;98:I-8.
60. Tcheng JE, Kereiakes DJ, Braden GA, **Lincoff AM**, Mascelli MA, Langral MA, Damaraju LV, Schantz AR, Barnathan ES, Efron MB. Safety of abciximab retreatment - final clinical report of the ReoPro Readministration Registry (R³). *Circulation* 1998;98:I-17.
61. Harrington RA, **Lincoff AM**, Berdan LG, MacAulay C, Kint P-P, Mahaffey KW, Kitt MM, Simoons ML, Califf RM. Maintenance of clinical benefit at six months in patients treated with platelet glycoprotein IIb/IIIa inhibitor eptifibatid versus placebo during an acute ischemic coronary event. *Circulation* 1998;98:I-359.
62. Ohman EM, **Lincoff AM**, Bode C, Bachinsky WB, Ardissino D, Matteo PS, Betriu A, Schildcrout JW, Oliverio R, Barnathan E, Sherer J, Sketch MS, Topol EJ. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction. Preliminary results from the GUSTO-4 Pilot (SPEED) dose ranging trial. *Circulation* 1998;98:I-504.
63. Rabbani R, Le Breton H, Khurana C, Forudi F, Plow EF, Mousa SA, **Lincoff AM**. The role of integrins $\alpha v\beta 3$ and $\alpha IIb\beta 3$ in an experimental arterial injury model. *Circulation* 1998;98:I-535.
64. Booth JE, Patel VB, Balog C, Miller DP, Juran NB, LeNarz L, **Lincoff AM**. Is bleeding risk increased in patients undergoing urgent coronary bypass surgery following abciximab. *Circulation* 1998;98:I-845.
65. Cura FA, L'Allier PL, Sapp S, **Lincoff AM**, Ellis SG, Topol EJ. Comparison of the protection against restenosis afforded by stenting or abciximab. *Journal of the American College of Cardiology* 1999;33:11A.
66. Foody JM, Balog C, Cho L, **Lincoff AM**, Topol EJ. Older women benefit from balloon PTCA rather than stenting when combined with IIb/IIIa anti-platelet therapy: a gender specific treatment interaction from EPISTENT. *Journal of the American College of Cardiology* 1999;33:12A.
67. Blankenship JC, Godfrey NK, Balog C, Demko SL, Califf RM, **Lincoff AM**, Tcheng JE, Topol EJ. CKMB enzyme rise after in-lab adverse events during coronary intervention in EPISTENT. *Journal of the American College of Cardiology* 1999;33:26A.
68. L'Allier PL, Cura FA, Sapp S, **Lincoff AM**, Topol EJ. EPISTENT: a large scale randomized trial of primary versus provisional coronary stenting with background platelet glycoprotein IIb/IIIa blockade. *Journal of the American College of Cardiology* 1999;33:32A.
69. Lauer MA, Zhou AM, Forudi F, **Lincoff AM**, Ellis SG, Topol EJ. The temperature of atherosclerotic lesions in the hypercholesterolemic rabbit double injury model is elevated following angioplasty. *Journal of the American College of Cardiology* 1999;33:67A.

70. Bajzer CT, Whitlow PL, **Lincoff AM**, Moliterno DJ, Topol EJ, Ellis SG. Coronary perforation and pericardial tamponade risk in the abciximab era. *Journal of the American College of Cardiology* 1999;33:72A.
71. Lorenz TJ, Greenberg S, Kleiman NS, Boersma E, **Lincoff AM**, Harrington RA, Kitt MM, Simoons ML. Eptifibatide during immediate percutaneous coronary intervention in the acute coronary syndromes: findings from the PURSUIT study. *Journal of the American College of Cardiology* 1999;33:72A.
72. Blankenship JC, Godfrey N, Demko SL, Califf RM, **Lincoff AM**, Tcheng JE, Topol EJ. Elimination of excess vascular access site bleeding during coronary intervention with abciximab. *Journal of the American College of Cardiology* 1999;33:73A.
73. Cura FA, L'Allier PL, Sapp S, **Lincoff AM**, Ellis SG, Topol EJ. A new precedent in percutaneous coronary intervention: less than 9% subsequent target vessel revascularization in a large-scale diverse patient, randomized trial of stenting. *Journal of the American College of Cardiology* 1999;33:83A.
74. Alexander JH, Sparapani RA, Mahaffey KW, Boersma E, **Lincoff AM**, Wilcox RG, Kitt MM, Simoons ML, Topol EJ, Califf RM, Harrington RA. Eptifibatide reduces the size and incidence of myocardial infarction in patients with non-ST-elevation acute coronary syndromes. *Journal of the American College of Cardiology* 1999;33:331A.
75. Bhatt DL, Houghtaling P, Harrington RA, **Lincoff AM**, Topol EJ. Black patients presenting with acute coronary syndromes have better outcomes due to less extent of disease. *Journal of the American College of Cardiology* 1999;33:365A.
76. Peterson J, Lauer MS, **Lincoff AM**, Sapp S, Topol EJ. Evidence for a potential adverse interaction between aspirin and angiotensin converting enzyme inhibitors after percutaneous coronary angioplasty: the EPILOG trial. *Journal of the American College of Cardiology* 1999;33:397A.
77. Bhatt DL, Marso SP, **Lincoff AM**, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces death in diabetics following percutaneous coronary intervention. *Circulation* 1999;100:I-67.
78. Hermann HC, Moliterno DJ, Bode C, Betriu A, **Lincoff AM**, Ohman EM. Combination abciximab and reduced-dose reteplase facilitates early PCI in acute MI: results from the SPEED trial. *Circulation* 1999;100:I-188.
79. Kleiman NS, **Lincoff AM**, Sapp SK, Maresh KJ, Topol EJ. Pharmacodynamics of a direct thrombin inhibitor combined with a GP IIb/IIIa antagonist: first experience in humans. *Circulation* 1999;100:I-328.
80. Ronner E, Harrington RA, **Lincoff AM**, Deckers JW, Simoons ML. Optimal timing of percutaneous intervention (PCI) in unstable angina. *Circulation* 1999;100:I-455.

81. Wang K, Zhou X, Zhou A, Forudi F, **Lincoff AM**. Recombinant soluble P-selectin glycoprotein ligand-1 attenuates P-selectin mediated inflammation and reperfusion injury in the canine model. *Circulation* 1999;100:I-614.
82. Tan WA, **Lincoff AM**, Jia G, Moliterno DJ. A prediction model to determine the incremental value (death or MI) of stenting, abciximab, or both according to risk stratum. *Circulation* 1999;100:I-733.
83. Marso SP, Bhatt DL, Sapp SK, Peterson JG, **Lincoff AM**, Topol EJ. Insulin resistance is predictive of clinical restenosis following percutaneous coronary revascularization. *Circulation* 1999;100:I-787.
84. Bhatt DL, **Lincoff AM**, Tcheng JE, Califf RM, L'Allier PL, Marso SP, Wolski KE, Kereiakes DJ, Topol EJ. The impact of abciximab on mortality after multivessel PCI: a striking effect in diabetics. *Journal of the American College of Cardiology* 2000;35:91A.
85. Kereiakes DJ, Berkowitz SD, **Lincoff AM**, Tcheng JE, Wolski K, Califf RM, Topol EJ. Abciximab thrombocytopenia: clinical correlates and outcomes. *Journal of the American College of Cardiology* 2000;35:91A.
86. Wang K, Zhou X, Zhou Z, Topol E, **Lincoff AM**. Sustained coronary artery recanalization with adjunctive infusion of a novel P2T-receptor antagonist AT-C69931 in a canine model. *Journal of the American College of Cardiology* 2000;35:281A.
87. Lauer MA, Mawhorter SD, Vince G, Al-Ahmadi MD, Bhatt DL, Hall GS, Fukamachi K, **Lincoff AM**, Topol EJ, Ellis SG. Increase in coronary artery matrix metallo-proteinases induced by intranasal chlamydia pneumoniae infection in a mini-pig model. *Journal of the American College of Cardiology* 2000;35:302A.
88. Roe MT, Harrington RA, Ohman EM, Califf RM, **Lincoff AM**, Bhatt DL, Prosper DM, Topol EJ. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. *Journal of the American College of Cardiology* 2000;35:347A.
89. Gassler JP, Silver MJ, Moliterno DJ, **Lincoff AM**, Ellis SG. Multivessel percutaneous coronary interventions during acute coronary syndromes appear to be safe in the glycoprotein IIb/IIIa antagonist era. *Journal of the American College of Cardiology* 2000;35:357A.
90. Mukherjee D, Wang K, Ellis SG, Silver M, Zhou X, Nimrod R, Topol EJ, **Lincoff AM**. Selective inhibition of factor Xa is more efficient than heparin at facilitating coronary thrombolysis in a canine model. *Journal of the American College of Cardiology* 2000;35:373A.
91. Aronow HD, Roe MT, Lauer MS, Houghtaling PS, **Lincoff AM**, Harrington RA, Califf RM, Topol EJ. Early and striking mortality reduction after acute coronary syndromes following lipid lowering therapy. *Journal of the American College of Cardiology* 2000;35:411A.
92. Zhou ZM, Marso SP, Schmidt AM, Stern DM, Wu Q, Forudi F, Wang K, **Lincoff AM**, Topol EJ. Blockade of receptor for advanced glycation end-products (RAGE) suppresses neointimal formation in diabetic rat carotid artery injury model. *Circulation* 2000;102:II-246.

93. Lev EI, Marmur JD, Zdravkovic M, Osende JI, Delfin JA, Richard M, Ezban M, Erhardtson E, Thomsen MS, **Lincoff AM**, Badimon JJ. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa; an ex vivo human study. *Circulation* 2000;102:II-300.
94. Wang K, Zhou ZM, **Lincoff AM**. Prevention of neointimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-Ig in the porcine coronary artery balloon injury model. *Circulation* 2000;102:II-329.
95. Tchong JE, Cohen EA, Buller CEH, **Lincoff AM**, Joseph D, Teirstein PS, Pacchiana CM, Madan M, Cantor WJ, Lorenz TJ, Kitt MM, O'Shea JC. High-dose eptifibatid (Integrilin) in coronary stent implantation: 6 month results of the ESPRIT trial. *Circulation* 2000;102:II-663.
96. Al-Khatib SM, Stebbins AL, **Lincoff AM**, Harrington RA. Ventricular arrhythmias in acute coronary syndromes without ST-segment elevation: incidence, predictors, and outcomes. *Circulation* 2000;102:II-675.
97. Bhatt DL, Chew DP, Simoons ML, Ommen SR, Gang J, Robbins MA, **Lincoff AM**. An elevated white blood cell count is an independent predictor of mortality in patients with acute coronary syndromes. *Circulation* 2000;102:II-776.
98. Chew DP, Bhatt DL, **Lincoff AM**, Brener SL, Wolski K, Topol EJ. Defining the optimal ACT during PCI: aggregate results from 5 large scale randomized trials. *Circulation* 2000;102:II-784.
99. Brener SJ, Apperson-Hanson C, Kleiman NS, Harrington RA, **Lincoff AM**, Alexander JH. "Spontaneous" vs inatrogenic myonecrosis: equivalent prognosis? *Circulation* 2000;102:II-797.
100. Bhatt DL, Chew DP, Robbins MA, Roffi M, Cho L, Yadav JS, **Lincoff AM**, Topol EJ, Ellis SG. Elevated baseline CRP levels predict death or MI in diabetic patients undergoing percutaneous coronary intervention. *Journal of the American College of Cardiology* 2001;37:66A.
101. Kleiman NS, **Lincoff AM**, Harrington RA, Sapp S, Wolski C, Topol EJ. Antithrombin, antiplatelet therapy or both during PCI: a preliminary randomized trail. *Journal of the American College of Cardiology* 2001;37:77A.
102. Wang K, Zhou Z, Zhou X, Rakji K, Qin JX, Sitges M, Shiota T, Topol EJ, **Lincoff AM**. Protection of left ventricular function with recombinant P-selectin glycoprotein ligand-Ig in the canine coronary balloon occlusion model. *Journal of the American College of Cardiology* 2001;37:369A.
103. Ellis BK, **Lincoff AM**, Sapp S. The effects of beta blocker therapy in patients with acute coronary syndromes undergoing percutaneous intervention: EPIC, CAPTURE, and RAPPORT data bases. *Journal of the American College of Cardiology* 2001;37:335A.
104. Akkerhuis M, Alexander JH, Tardiff BE, Boersma E, Harrington RA, **Lincoff AM**, Simoons ML. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? *Journal of the American College of Cardiology* 2001;37:355A.

105. Cohen EA, **Lincoff AM**, Sapp S, Burton JR, Tcheng JE, Topol EJ, EPISTENT Investigators. Variations in event rates between Canada and United States in the EPISTENT trial. *Journal of the American College of Cardiology* 2001;37:81A.
106. Wang K, Tarakji K, Zhou Z, Forudi F, Keller B, Zhou X, **Lincoff AM**. Inhibition of neointimal hyperplasia by a potent selective cyclooxygenase-2 inhibitor in the rabbit atherosclerotic balloon injury model. *Circulation* 2001;104:II-91.
107. Wang K, Zhou X, Zhou Z, Tarakji K, Carneiro M, Murray RD, Klein AL, **Lincoff AM**. Blockade of the ADP P2T receptor sustains coronary artery recanalization and improves the myocardium tissue perfusion in a canine thrombosis model.. *Circulation* 2001;104:II-96.
108. Bhatt DL, **Lincoff AM** on behalf of the CRUISE Investigators. Combined use of eptifibatid and enoxaparin in patients undergoing percutaneous coronary intervention: the results of the CRUISE trial.. *Circulation* 2001;104:II-384.
109. Quinn MJ, **Lincoff AM**, Kerieakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, Tcheng JE, Califf RM, Topol EJ. Long-term mortality benefit of abcixmab in percutaneous intervention.. *Circulation* 2001;104:II-387.
110. Gurm HS, Askari AT, Tang W, Prosper D, **Lincoff AM**. The impact of creatinine clearance on 6 month outcome after percutaneous coronary interventions.. *Circulation* 2001;104:II-742.
111. Bhatt DL, Cho L, **Lincoff AM**, Bittl JA, Topol EJ. Reduction in percutaneous coronary intervention-related bleeding with bivalirudin is particularly striking in women. *Journal of the American College of Cardiology* 2002;39:17A.
112. Cho L, Reginelli J, **Lincoff AM**, Roffi M, Kaldus T, Kottke-Marchant K, Mize PD, Moliterno DJ. A new rapid ecarin clotting time assay but not activated clotting time strongly correlates with bivalirudin concentration: a percutaneous coronary intervention study. *Journal of the American College of Cardiology* 2002;39:17A.
113. Aronow HD, Quinn MJ, Gurm HS, Topol EJ, **Lincoff M**, Brennan, DM, Lauer MS. Myocardial necrosis is halved in patients undergoing elective percutaneous coronary intervention who are pretreated with lipid-lowering therapy. *Journal of the American College of Cardiology* 2002;39:32A.
114. Reginelli JP, Cho L, Dauterman K, Lee D, **Lincoff AM**. Ionic contrast substantially increases the activated clotting time in patients receiving abciximab and bivalirudin at the time of percutaneous coronary intervention. *Journal of the American College of Cardiology* 2002;39:49A.
115. Zhou Z, Wang K, Forudi F, Zhou X, Tarakji K, Penn MS, **Lincoff AM**. P-selectin neutralization prevents neotimal formation in a diabetic rat model. *Journal of the American College of Cardiology* 2002;39:53A.
116. Alexander JH, Dyke CK, Becker RC, Yang H, Robertson TL, Kunitada S, Zillman LA, Cohen EA, Bovill EG, Berger PB, **Lincoff M**, Hochman JS, Armstrong PW, Kleiman NS, Harrington RA. Initial experience with a novel direct factor Xa inhibitor in percutaneous coronary intervention. *Journal of the American College of Cardiology* 2002;39:73A.

117. Gurm HS, Tang WHW, Lee D, Jia G, **Lincoff AM**, Topol EJ. Improving outcome in treatment of diabetics with ST elevation myocardial infarction: insights from the GUSTO trials. *Journal of the American College of Cardiology* 2002;39:292A.
118. Mukherjee D, Gurm H, Tang WHW, Roffi M, Wolski K, Moliterno DJ, Guetta V, Ardissino D, Bode C, Steg G, **Lincoff AM**, Topol EJ. Improved outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery treated with combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. *Journal of the American College of Cardiology* 2002;39:293A.
119. Ohman EM, Califf RM, **Lincoff M**, Armstrong P, Kleiman N, Hochman J, White H, Savonitto S, Piedmonte M, Booth J, Topol EJ. Prevention of reinfarction using half-dose reteplase and abciximab: observations from the GUSTO-5 trial. *Journal of the American College of Cardiology* 2002;39:305A.
120. Krucoff MW, Green CL, Langer A, Gibler B, Armstrong PW, Trollinger KM, Crater SW, **Lincoff AM**, Califf RM, Topol EJ. The Abciximab ST-Recovery ON AMI (ASTRONAMI) GUSTO V substudy: enhanced early speed, stability, and quality of reperfusion with antiplatelet augmented thrombolytic therapy for ST-elevation MI. *Journal of the American College of Cardiology* 2002;39:306A.
121. Gum PA, Steinhubl SR, Lever HM, van Lente F, Tuzcu EM, **Lincoff AM**. Cardiac serum marker release after percutaneous transluminal septal myocardial ablation: a human model. *Journal of the American College of Cardiology* 2002;39:312A.
122. Aronow HD, McRae T, Quinn MJ, Topol EJ, **Lincoff AM**, Houghtaling PL, Lauer MS. Patients on lipid-lowering therapy at the time of a myocardial infarction have smaller infarcts: further evidence to suggest a salutary effect in acute coronary syndromes. *Journal of the American College of Cardiology* 2002;39:318A.
123. Krucoff MW, Green CL, Crater SW, Johanson P, **Lincoff AM**, Gibler WB, Langer A. Continuous ST-segment deviation curve area in acute ST-elevation MI (STEMI): Antiplatelet treatment response and clinical outcomes correlation. *Circulation* 2002;106:II-373.
124. Cho L, Chew DP, Roffi M, Moliterno DJ, Reginelli J, Aronow H, Chan A, Quinn M, Gum P, **Lincoff AM**. Bivalirudin appears to be safe and efficacious with GP IIb/IIIa inhibitors. *Circulation* 2002;106:II-494.
125. Cura FA, Roffi M, Pasca N, Wolski KE, **Lincoff AM**, Lauer MS. Predictors for lack of reperfusion after thrombolytics in acute myocardial infarction. *Circulation* 2002;106:II-630.
126. Gurm HS, Aronow HD, Askari AT, Brennan D, **Lincoff AM**, Topol EJ. Renal insufficiency and anemia in patients undergoing percutaneous coronary interventions: a double jeopardy. *Journal of the American College of Cardiology* 2003;41:11A.

127. Aronow HD, Quinn MJ, Gurm HS, Lauer MS, Brennan DM, Topol EJ, **Lincoff AM**. Preprocedure inflammatory state predicts periprocedural myocardial infarction after elective percutaneous coronary intervention: an EPIC substudy. *Journal of the American College of Cardiology* 2003;41:17A.
128. Feit F, Bittl AJ, **Lincoff AM**, Chew DP, Kleiman NS, Waloentin L, White HD, Orniston J, Robson R, Aylward PE, Attubato J. Bivalirudin reduces ischemic and hemorrhagic complications of percutaneous coronary intervention: pooled data from 10 prospective studies in 6134 patients. *Journal of the American College of Cardiology* 2003;41:25A.
129. Wang K, Fan L, Zhou Z, Forudi F, Zhou X, **Lincoff AM**, Topol EJ, Penn MS. Activation of peroxisome proliferator activated receptor gamma inhibits neointimal formation in a diabetic rat carotid artery injury model. *Journal of the American College of Cardiology* 2003;41:33A.
130. Dery JP, Braden GA, **Lincoff AM**, Kereiakes DJ, Browne KF, Little T, George BS, Effron MB, Mascelli MA, Langrall MA, Damaraju L, Barnathan ES, Tchong JE. Abciximab readministration: final results of the ReoPro Readministration Registry. *Journal of the American College of Cardiology* 2003;41:77A.
131. Chew DP, Bhatt DL, Berger PB, Henry T, McCullough PA, Feit F, Bittl JA, **Lincoff AM**. Bivalirudin provides increasing benefit with declining renal function in percutaneous coronary intervention: a meta-analysis of 5035 patients enrolled in three randomized trials. *Journal of the American College of Cardiology* 2003;41:83A.
132. Roe MT, Giugliano RP, Tuttle R, Hasselblad V, Murphy S, Antman EM, Ohman EM, Harrington RA, Granger CB, Mahaffey KW, Cannon CP, **Lincoff AM**, Gibson CM, Armstrong PW, van de Werf FJ, Califf RM, Topol EJ, Braunwald E. Safety of adjunctive glycoprotein IIb/IIIa blockade during rescue/early percutaneous coronary intervention following full-dose fibrinolytic therapy for acute myocardial infarction. *Journal of the American College of Cardiology* 2003;41:332A.
133. Krucoff MW, Green CL, Johanson P, Crater SW, Roe MT, Langer A, Giugliano FP, **Lincoff AM**, Harrington RA, Topol EJ, Califf RM. Opening the window of facilitated percutaneous coronary intervention in acute infarction: the role of combined IIb/IIIa inhibition and thrombolytic therapy. *Journal of the American College of Cardiology* 2003;41:334A.
134. Srichai MB, Harrington RA, Hochman JS, Houghtaling PL, Velazquez EJ, **Lincoff AM**, Simoons ML, Jaber WA. In-hospital and discharge utilization of medications in patients with and without heart failure presenting with acute coronary syndromes. Insights from the PURSUIT study. *Journal of the American College of Cardiology* 2003;41:382A.
135. Kaldus T, Cho L, Davis R, Swan H, **Lincoff AM**, Moliterno DJ, Kottke-Marchant K. Issues in monitoring direct thrombin inhibitors: comparison of a new, rapid Ecarin Clotting Time (ECT) test to activated clotting time (ACT) and anti-IIa assays. *Journal of Thrombosis & Haemostasis* 2003; Suppl 1;P1910.
136. Zhou X, Mukherjee D, Zhou Z, **Lincoff AM**, Wang K. A combination of a selective factor Xa inhibitor and full dose tPA is more effective than heparin and full dose tPA at facilitating coronary thrombolysis in a canine model. *European Heart Journal* 2003;24(Abstract Supplement);545.

137. Desmet W, Saw J, **Lincoff AM**, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Topol EJ on behalf of the REPLACE-2 Investigators. Does clopidogrel pretreatment influence the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade? A REPLACE-2 substudy. *European Heart Journal* 2003;24(Abstract Supplement);548.
138. Burger DG, Jia G, **Lincoff AM**, Feit F, Kleiman NS. Multivessel percutaneous coronary intervention and lesion characteristics predict risk for death/myocardial infarction even in the modern stent era: lessons from the REPLACE-2 trial. *Circulation* 2003;108:IV-459.
139. **Lincoff AM**, Topol EJ. Long-term efficacy of bivalirudin and provisional GP IIb/IIIa blockade compared with heparin and planned GP IIb/IIIa blockade during percutaneous coronary intervention: 6-month and 1-year results of the REPLACE-2 trial. *Circulation* 2003;108:IV-569.
140. Saw J, Desmet W, **Lincoff AM**, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Topol EJ. Clopidogrel pretreatment does not influence the relative efficacy of bivalirudin with provisional GP IIb/IIIa blockade vs heparin with routine GP IIb/IIIa blockade. A REPLACE-2 substudy. *Circulation* 2003;108:IV-570.
141. Vivekananthan D, Kottke-Marchant K, Wolski K, **Lincoff AM**. Reduction of rebound thrombin generation with use of bivalirudin during percutaneous coronary intervention. *Circulation* 2003;108:IV-570.
142. Cohen DJ, Lavelle T, Chen H-L, Berezin RH, Bakhai A, Plent S, **Lincoff AM**. Cost effectiveness of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin + routine glycoprotein IIb/IIIa inhibition for contemporary PCI: results from the REPLACE-2 trial. *Circulation* 2003;108:IV-570.
143. Armstrong PW, Kaul P, Ardissino D, Aylward P, Bar FW, Betriu A, Bode C, Guetta V, Steg G, Van de Werf F, **Lincoff M**. What is an optimal rate of early revascularization after ST-elevation myocardial infarction? Insights from the GUSTO-V trial. *Circulation* 2003;108:IV-613.
144. Gavlik K, Blankenship JC, Kleiman NS, Bittl JA, Feit F, Topol EJ, **Lincoff AM**. Procedural predictors of creatine kinase-MB elevations in the REPLACE-2 study. *Journal of the American College of Cardiology* 2004;43:44A.
145. Reynold HR, Farkouh ME, Swahn E, White JA, Sadowski ZP, **Lincoff AM**, Topol EJ, Hochman JS. Female sex: a more important prognostic marker than treatment assignment or comorbid conditions among patients with acute myocardial infarction in the GUSTO V trial. *Journal of the American College of Cardiology* 2004;43:261A.
146. Vivekananthan DP, **Lincoff AM**, Gurm HS, Brennan D, Topol EJ. Use of angiotensin-converting enzyme inhibitors after acute myocardial infarction is associated with a striking reduction in 30-day and one-year mortality: insights from GUSTO V. *Journal of the American College of Cardiology* 2004;43:286A.

147. Alexander JH, Yang H, Becker RC, Kodama K, Dyke CK, Goodman SG, Kleiman NS, Hochman JS, Berger PB, Cohen EA, **Lincoff AM**, Bovill EG, Kawai C, Armstrong PW, Harrington RA. Direct selective factor Xa inhibition in patients with non-ST elevation acute coronary syndromes from the United States, Canada, and Japan: results of the XaNADU-ACS trial. *Journal of the American College of Cardiology* 2004;43:302A.

INVITED PRESENTATIONS AND AUDIO-VISUAL EDUCATIONAL MATERIALS:

1993

"Indications and Contraindications to Thrombolytic Therapy, 1993," Acute Decisions, The Cleveland Clinic Foundation, Cleveland, Ohio, June 23, 1993.

"Indications and Contraindications for Thrombolytic Therapy." Medical News Network, December, 1993.

1994

"Local Drug Delivery for the Prevention of Restenosis." Heart Center Grand Rounds, The Cleveland Clinic Foundation, Cleveland, Ohio, January 7, 1994.

"Local Drug Delivery in the Coronary Arteries." American College of Cardiology Extended Learning Series (ACCEL). Recorded March 13, 1994.

"The Illusion of Reperfusion." Medical Grand Rounds, Mercy Medical Center, Baltimore, Maryland, March 30, 1994.

"Local Drug Delivery for the Prevention of Restenosis Following Percutaneous Coronary Revascularization." Bioengineering Seminar, Department of Biomedical Engineering, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, April 29, 1994.

"What is the Most Effective Thrombolytic Regimen?" Medical Management of Heart Disease, The University of Kansas School of Medicine, Wichita, Kansas, May 6, 1994.

"Adjunctive Therapy for Acute Myocardial Infarction." Medical Management of Heart Disease, The University of Kansas School of Medicine, Wichita, Kansas, May 6, 1994.

"Treating Acute Myocardial Infarction." Medical Management of Heart Disease, The University of Kansas School of Medicine, Wichita, Kansas, May 7, 1994.

"Animal Models of Restenosis." Restenosis Summit VI, The Cleveland Clinic Foundation, Cleveland, Ohio, May 13, 1994.

"Local Delivery in Restenosis." Investigator Task Force, Schneider (USA), Inc., Minneapolis, MN, May 27, 1994.

"Drug Delivery Systems." Cardiac Catheterization Laboratory Conference, Tel Aviv Medical Center, Tel Aviv, Israel, June 12, 1994.

"Illusion of Reperfusion." Department of Cardiology Journal Club, Tel Aviv Medical Center, Tel Aviv, Israel, June 13, 1994.

"Local Drug Delivery for Treatment of Restenosis." Biotechnology General, Ltd, Rehovot, Israel, June 14, 1994.

"Assessment of Risk for PTCA." *Journal of Invasive Cardiology* Round Table Discussion: Improving Outcomes in Patients at Higher Risk of Ischemic Complications During and After PTCA. Amelia Island, Florida, July 9, 1994.

"Local Delivery of Therapeutic Agents During PTCA." American Society of Cardiovascular Professionals Annual Meeting, Pittsburgh, Pennsylvania, September 10, 1994.

"Local Drug Delivery for Prevention of Restenosis Following Percutaneous Coronary Revascularization." University of Chicago, Division of Cardiology Research Conference, Chicago, Illinois, October 21, 1994.

"Novel Anti-Platelet and Anti-Thrombin Strategies in the Treatment of Coronary Artery Disease." Factor VIIa Inhibitor Workshop, Zymogenetics, Inc., Seattle, Washington, October 24, 1994.

"Striking Clinical Benefit with Platelet GP IIb/IIIa Inhibition by c7E3 Among Patients with Unstable Angina: Outcome in the EPIC Trial." American College of Cardiology Extended Learning Series (ACCEL). Recorded November 15, 1994.

"Interventional Cardiology Devices." Polymers in Medicine, Case Western Reserve University Department of Biomedical Engineering, Cleveland, Ohio, December 7, 1994.

"Use of c7E3 in the Setting of PTCA (Results of the EPIC Trial)." Second Joint Meeting of the Belgian and Dutch Working Group on Interventional Cardiology, Brussels, Belgium, December 9, 1994.

1995

"Update on Coronary Thrombolysis." Visiting Consultant Lecture Series. St. Joseph Riverside Hospital, Warren, Ohio, February 11, 1995.

"Platelet GP IIb/IIIa Inhibition by c7E3 Among Patients with Unstable Angina Undergoing Percutaneous Revascularization: Outcome in the EPIC Trial." International Congress on Endovascular Interventions VIII, Phoenix, Arizona, February 15, 1995.

"Mechanical Characteristics of the Dispatch Catheter." Transcatheter Cardiovascular Therapeutics VII, The Washington Hospital Center, Washington, D.C., February 23, 1995.

"Case Selection for Use of the Platelet Glycoprotein IIb/IIIa Receptor Inhibitor During Angioplasty." Transcatheter Cardiovascular Therapeutics VII, The Washington Hospital Center, Washington, D.C., February 23, 1995.

"Principles, Pitfalls, and Promise of Local Drug Delivery: An Overview." Transcatheter Cardiovascular Therapeutics VII, The Washington Hospital Center, Washington, D.C., February 25, 1995.

"The Cordis Microporous Balloon." Transcatheter Cardiovascular Therapeutics VII, The Washington Hospital Center, Washington, D.C., February 25, 1995.

"Prospects for Platelet GP IIb/IIIa Antagonists in Acute Myocardial Infarction." Myocardial Reperfusion Concepts and Controversies, Cleveland Clinic Foundation Satellite Conference at American College of Cardiology Meeting, New Orleans, Louisiana, March 18, 1995.

"New Advances in Angioplasty and the EPIC Trial." Cardiology Grand Rounds, Lankenau Hospital, Philadelphia, Pennsylvania, April 5, 1995.

"Do Adjunctive Therapies Improve Outcome During Coronary Angioplasty." Cardiology Grand Rounds, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, April 5, 1995.

"Use of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Coronary Artery Disease." Cardiac Catheterization Conference, Division of Cardiology, Temple University, April 6, 1995.

"Platelet GP IIb/IIIa Inhibition in Acute Myocardial Infarction." Antithrombotic Therapy and Post-Myocardial Infarction Management in Ischaemic Heart Disease. McMaster University Symposium, Hamilton, Ontario, Canada, April 29, 1995.

"Quantitative Assessment of Local Delivery and Delivery Stents." Restenosis Summit VII, The Cleveland Clinic Foundation, Cleveland, Ohio, May 19, 1995.

"Platelet Integrin Blockade in Cardiovascular Disease." Dynamics of Hemostasis and Thrombophilia in Critical Care. National Antithrombin Investigators Meeting, Georgetown University, Naples, Florida, May 20, 1995.

"Restenosis Following Percutaneous Coronary Intervention." Medical Division Grand Rounds, The Cleveland Clinic Foundation, Cleveland, Ohio, June 1, 1995.

"Treatment of the Complex Coronary Lesion." Interventional Rounds, The University of Minnesota, St. Paul, Minnesota, June 2, 1995.

"Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Cardiovascular Disease." Stanford University Catheterization Conference, Palo Alto, California, June 22, 1995.

"The Role of GP IIb/IIIa Receptor Blockers in PTCA." Section of Cardiology, Christ Hospital/Rush University, Chicago, Illinois, June 29, 1995.

"Heparin Dosing and Control of Bleeding with 7E3 Therapy During Percutaneous Coronary Intervention." Evolution of Clinical Applications of ReoPro. *Journal of Invasive Cardiology* Roundtable. Amelia Island, Florida, July 22, 1995.

"IMPACT II: Integrelin (Platelet Glycoprotein IIb/IIIa Receptor Blocker) in Coronary Angioplasty. Clinical and Angiographic Endpoints." Hot Line III, European Society of Cardiology Congress, Amsterdam, The Netherlands, August 24, 1995.

"Mechanism and Prevention of Abrupt Closure in PTCA." Improving Clinical Outcome in the High-Risk PTCA Patient. The Cleveland Clinic Foundation, Cleveland, Ohio, August 29, 1995.

"Results of the EPIC Trial." New Perspectives in Platelet Inhibition: Glycoprotein IIb/IIIa Antagonists. Inselspital Bern, Switzerland, September 14, 1995.

"Local Drug Delivery - Theoretical and Practical Aspects." Joint Symposium of the Austrian Working Groups for Interventional Cardiology and Experimental Cardiology, Annual Meeting of the Austrian Society for Internal Medicine, Graz, Austria, September 22, 1995.

"Overview of Human Applications for Local Drug Delivery." First Annual International Symposium on Local Cardiovascular Drug Delivery. Massachusetts Institute of Technology, Boston, Massachusetts, September 29, 1995.

"Pharmacologic Adjuncts to PTCA: Current Status." Eighth Annual Advances in Interventional Cardiology Symposium. William Beaumont Hospital, Troy, Michigan, October 2, 1995.

"Adjunctive Antiplatelet and Antithrombin Strategies During Coronary Intervention and Unstable Angina." Emergency Department Grand Rounds, The Cleveland Clinic Foundation, October 5, 1995.

"Local Drug Delivery - Clinical Indications and Catheter Selection." Coronary Interventions 1995, Scripps Clinic and Research Foundation, La Jolla, California, October 21, 1995.

"Antithrombin and Antiplatelet Strategies." Hemostasis and Thrombosis Second Annual Symposium, Overlook Hospital, Summit, New Jersey, October 31, 1995.

"The Role of GP IIb/IIIa Receptor Blockers in PTCA." Interventional Cardiology Conference, Academic Medical Center, Amsterdam, The Netherlands, November 28, 1995.

"Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Cardiovascular Disease." Academic Hospital, Utrecht, The Netherlands, November 29, 1995.

"Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Cardiovascular Disease." University of Hamburg, Hamburg, Germany, November 30, 1995.

Visiting Professorship, St. Luke's Episcopal Hospital and the Texas Heart Institute. "New Therapeutic Approaches for Prevention of Restenosis," Cardiology Basic Science Conference. "Platelet Integrin Receptor Blockade in Coronary Artery Disease," Cardiology Grand Rounds, Houston, Texas, December 15, 1995.

1996

"Platelet Integrin Receptor Blockade in Coronary Artery Disease." St. Louis Regional Interventional Cardiology Conference, St. Louis, Missouri, January 17, 1996.

"Local Cardiovascular Drug Delivery." 78th Japanese Cineangiography Meeting, Osaka, Japan, January 20, 1996.

"Advantages and Limitations of Currently-Available Catheter Designs" and "Coated Stents." Antithrombotic Therapy in Stenting Retreat, Cardiology Research Foundation, Washington, D.C., January 27, 1996.

"Platelet Glycoprotein IIb/IIIa Receptor Antagonists During Coronary Intervention." Current Concepts and Controversies in Cardiology, Johannesburg, South Africa, February 19, 1996.

"Thirty-Day Safety Data from IMPACT II." Integrilin Investigators Meeting, Washington, D.C., February 28, 1996.

"Pitfalls and Obstacles to the Use of IIb/IIIa Blockade During PTCA." Transcatheter Cardiovascular Therapeutics VIII, The Washington Hospital Center, Washington, D.C., February 29, 1996.

"An Overview of Local Drug Delivery: Principles, Pitfalls, and Promise." Transcatheter Cardiovascular Therapeutics VIII, The Washington Hospital Center, Washington, D.C., March 1, 1996.

"The Next Generation of Anti-Thrombotic Agents." Transcatheter Cardiovascular Therapeutics VIII, The Washington Hospital Center, Washington, D.C., March 2, 1996.

"Glycoprotein IIb/IIIa Receptor Blockade During Coronary Intervention." Yonsei University, Seoul, Korea, March 14, 1996.

"Current Trials for Prevention of Restenosis." International Symposium on Ischemic Cardiovascular Diseases, Chonnam University Hospital, Kwangju, Korea, March 15, 1996.

"Limitations and Obstacles to the Use of IIb/IIIa Blockade." The Era of Platelet GP IIb/IIIa Blockade. American College of Cardiology Satellite Symposium, Orlando, Florida, March 23, 1996.

"Evaluation of PTCA to Improve Long-Term Outcome by c7E3 Glycoprotein IIb/IIIa Receptor Blockade (EPILOG)." Major Clinical Trials V: Interventional Therapy. American College of Cardiology 45th Annual Scientific Session, Orlando, Florida, March 27, 1995.

"Primary Angioplasty vs Thrombolytic Therapy." Sixteenth Annual Dimensions in Cardiac Care. The Cleveland Clinic Foundation, Cleveland, Ohio, April 2, 1996.

"GP IIb/IIIa Receptor Blockade: Its Clinical Utility in Interventional Cardiology and Unstable Angina." The Relevance of Thrombosis in Coronary Intervention. London Chest Hospital, London, England, April 26, 1996.

"Intracoronary Catheters, Atherectomy Devices, and Intracoronary Stents." *Polymers in Medicine*, Case Western Reserve University, Cleveland, Ohio, May 1, 1996.

"Specific Platelet IIb/IIIa Receptor Blockers to Avoid Thrombotic Occlusion and Restenosis During and After Coronary Intervention." *Prevention and Management of Thrombotic Complications During Coronary Interventions*, European Society of Cardiology, European Heart House, Sophia Antipolis, France, May 9, 1996.

Visiting Professorship, University of Texas. "Glycoprotein IIb/IIIa Inhibition in Cardiovascular Disease," *Cardiology Grand Rounds*, Houston, Texas, June 6, 1996.

"Antiplatelet/Thrombolytic Drugs in Ischemic Syndromes." *Fourth Pacific Northwest Cardiovascular Symposium*. Seattle, Washington, June 13, 1996.

"Platelet Glycoprotein IIb/IIIa Receptor Blockade in Interventional Cardiology." *Interventional Cardiology Toward the Third Millennium*. New York, New York, June 18, 1996.

"Debate on Coronary Debulking - The Case Against Rotablation and Directional Atherectomy." *Interventional Cardiology Toward the Third Millennium*. Newark, New Jersey, July 16, 1996.

"EPIC and EPILOG in Perspective. How Will They Change Interventional Practice?" *High Risk Angioplasty: Pharmacology, Theory, and Practice*, Mayo Clinic Foundation, Minneapolis, Minnesota, July 20, 1996.

"Coated and Eluting Stents." *XVIIIth Congress of the European Society of Cardiology*. Birmingham, England, August 26, 1996.

"GP IIb/IIIa Receptor Blockade: Indications in Patients at High Risk or Low Risk for Percutaneous Transluminal Coronary Procedures. The EPIC and EPILOG Studies." *An Exploration of Present and Future Applications of GP IIb/IIIa Inhibitors*. XVIIIth Congress of the European Society of Cardiology. Birmingham, England, August 28, 1996.

"Overview of Platelet IIb/IIIa Blockade in Interventional Cardiology." *Prevention and Management of Thrombotic Complications During Coronary Intervention Scandinavian Meeting*, Marienlyst, Denmark, September 5, 1996.

"Platelet Integrin Receptor Blockade in Cardiovascular Disease." *Israel Society of Interventional Cardiology Semi-Annual Meeting*, Tel Aviv, Israel, September 8, 1996.

"Adjunctive Antiplatelet Therapy During Coronary Intervention." *Yale University School of Medicine, Cardiology Grand Rounds*, New Haven, Connecticut, September 27, 1996.

"Sustained Release Matrices for Intravascular Drug Delivery." *Research Update Symposium 1996*, Center for Cardiovascular Biomaterials, Case Western Reserve University, Cleveland, Ohio, October 29, 1996.

"EPIC and EPILOG" and "Summary of GP IIb/IIIa Interventional Trials." *1996 Cardiovascular Global Medical Conference*, Eli Lilly and Company, Indianapolis, Indiana, November 8, 1996.

"Platelet Glycoprotein IIb/IIIa Receptor Blockade During Coronary Intervention." Columbia Presbyterian University Hospital Cardiology Grand Rounds, New York, New York, December 18, 1996.

1997

"Glycoprotein IIb/IIIa Blockade in Coronary Intervention." Cardiology Grand Rounds, The Prince Charles Hospital, Brisbane, Australia, February 28, 1997.

"Interventions in Unstable Angina." Problem Solving in Interventional Cardiology: The CLINICS' Approach," Anaheim, California, March 15, 1997.

"Progress in the Development of Drug Delivery Stents." Meet the Experts Session, American College of Cardiology 46th Annual Scientific Session, Anaheim, California, March 18, 1997.

"Antiplatelet Therapy During Coronary Intervention and Acute Ischemic Syndromes." Cardiology Staff Conference, Ohio State University, Columbus, Ohio, April 4, 1997.

"Advances in Acute Coronary Syndromes." Seventeenth Annual Dimensions in Cardiac Care, The Cleveland Clinic Foundation Division of Patient Care Operations, Cleveland, Ohio, April 8, 1997.

"Point of View - New Antiplatelet Agents in Interventional Cardiology." XI Practical Course in Interventional Cardiology, Madrid, Spain, April 18, 1997.

"The Vitronectin Receptor." Restenosis Summit IX, The Cleveland Clinic Foundation, Cleveland, Ohio, May 16, 1997.

"Update on Restenosis." Cardiology Grand Rounds, University of Alberta, Edmonton, Alberta, May 21, 1997.

"EPILOG and Beyond: Lessons Learned and New Questions Raised." First International Preceptorship in Interventional Cardiology. Christ Hospital, Cincinnati, Ohio, May 30, 1997.

"Targeted Drug Delivery Systems." First International Preceptorship in Interventional Cardiology. Christ Hospital, Cincinnati, Ohio, May 30, 1997.

"Economics of GP IIb/IIIa Blockade Revisited." First International Preceptorship in Interventional Cardiology. Christ Hospital, Cincinnati, Ohio, May 30, 1997.

"Passivation of the Arterial Wall: Is it the Magic Bullet?" European Restenosis Summit, European Society of Cardiology, Lille France, June 13, 1997.

"Local Drug Delivery Stents." European Restenosis Summit, European Society of Cardiology, Lille France, June 13, 1997.

"Platelet Integrin Blockade in Cardiovascular Disease." Japanese Society of Interventional Cardiology 6th Annual Meeting, Tokyo, Japan, June 27, 1997.

"Platelet Glycoprotein IIb/IIIa Blockade in Interventional Cardiology." Second International Meeting on Interventional Cardiology, Jerusalem, Israel, July 2, 1997.

"Coagulation and Thrombosis: Review of New Platelet Aggregation Inhibitors." Second Meeting of the Latin American Society for Interventional Cardiology, Buenos Aires, Argentina, August 2, 1997.

"Restenosis: Local Drug Delivery." Second Meeting of the Latin American Society for Interventional Cardiology, Buenos Aires, Argentina, August 2, 1997.

"Platelet GP IIb/IIIa Receptor Blockade in Interventional Cardiology." 1st International Congress on Coronary Artery Disease - From Prevention to Intervention, Prague, The Czech Republic, September 23, 1997.

"Clinical Studies Update - Abciximab and Tirofiban." Managing Unstable Angina: New Considerations for Interventional Practice, Evening Satellite Symposium, Transcatheter Cardiovascular Therapeutics IX, Washington, D.C., September 24, 1997.

"t-PA and Integrilin." Second International Thrombolytic Collegium, The Next Era of Reperfusion, Boston, MA, September 27, 1997.

"GP IIb/IIIa Inhibitors: Clinical Trial Overview." Eli Lilly Global Medical Conference, Indianapolis, IN, November 7, 1997.

"Status of GP IIb/IIIa Inhibitors in Interventions." Hirulog Experts Meeting, Orlando, Florida, November 8, 1997.

"Significant PURSUIT Substudy Results." New Directions in the Management of Patients with Unstable Angina and Non-Q wave Myocardial Infarction. Orlando, Florida, November 8, 1997.

1998

"Angiographic Interventions in PURSUIT." Presentation to Cardiovascular and Renal Drugs Advisory Committee for NDA 20-718, Integrilin (eptifibatide) injection, COR Therapeutics, for use in settings of percutaneous transluminal angioplasty and acute coronary syndrome. Food and Drug Administration, Washington, D.C., January 28, 1998.

"Platelet Inhibition, Thrombosis, and Restenosis" and "Use of Antiplatelet Agents and Anticoagulation in PTCA." National Heart Centre of Singapore Seventh Live Demonstration Course in Interventional Cardiology, Singapore, February, 17, 1998.

"Antiplatelet GP IIb/IIIa Blockade in Clinical Practice." Heart Association of Thailand, Bangkok, Thailand, February 19, 1998.

"The Emerging Role of GP IIb/IIIa Receptor Antagonists in Interventional Cardiology." Kuala Lumpur, Malaysia, February 20, 1998.

"GP IIb/IIIa Inhibition in Interventional Cardiology." Antithrombotic Strategies in Acute Coronary Syndromes. Uppsala Cardiothoracic Center, Stockholm, Sweden, March 5, 1998.

“Overview of Trials with GP IIb-IIIa Inhibitors in the Setting of Percutaneous Transluminal Coronary Angioplasty.” Insights in the Management of Acute Ischemic Coronary Syndromes: A Program for Cardiology Fellows. Satellite Symposium of the American College of Cardiology Meeting, Atlanta, Georgia, March 27, 1998.

“Status of IIb/IIIa’s for Interventions.” Anticoagulant Therapy: New Promises and Challenges. Satellite Symposium of the American College of Cardiology Meeting, Atlanta, Georgia, March 28, 1998.

“Anti-thrombotic Treatment in CAD.” Risk Factor Management Update. Satellite Symposium of the American College of Cardiology Meeting, Atlanta, Georgia, March 28, 1998.

“Stents and Abciximab: The EPILOG Stent Trial.” Myocardial Reperfusion XI: Concepts and Controversies. Satellite Symposium of the American College of Cardiology Meeting, Atlanta, Georgia, March 28, 1998.

“Early Invasive versus Conservative Management: Results from PURSUIT.” The Dawn of a New Era in the Management of Acute Ischemic Coronary Syndromes. Satellite Symposium of the American College of Cardiology Meeting, Atlanta, Georgia, March 28, 1998.

“Direct Thrombin Inhibition and Platelet Glycoprotein IIb/IIIa Receptor Blockade: What Will the CACHET Trial Teach Us?” Acute Coronary Syndromes: Theory and Practice in Evolution. Satellite Symposium of the American College of Cardiology Meeting, Atlanta, Georgia, March 28, 1998.

“Optimal Management of Acute Myocardial Infarction.” Luncheon Panel, American College of Cardiology Meeting, Atlanta, Georgia, March 30, 1998.

“Indications for IIb/IIIa Inhibitors.” Meet the Experts Session, American College of Cardiology Meeting, Atlanta, Georgia, March 31, 1998.

“Glycoprotein IIb/IIIa Inhibition in Combination with Stents: EPILOG Stent 30 Day Data.” Endovascular Therapy Course, Paris, France, May 6, 1998.

“Platelet GP IIb/IIIa Receptor Blockade and Stents.” Cleveland Clinic Foundation Heart Center Grand Rounds, Cleveland, Ohio, May 13, 1998.

“Update on GP IIb/IIIa Receptor Blockade - Latest Study Results.” Ten Years of Coronary Stent Implantation and Rotablation in Germany, University of Essen, Essen, Germany, May 14, 1998.

“Update on Clinical Trials with Abciximab.” GP IIb/IIIa Antagonists for Treatment of Acute Coronary Syndromes - Latest Study Results and Clinical Impact, Deutsches Herzzentrum, Munich, Germany, May 15, 1998.

“GP IIb/IIIa Inhibitors: Results of Major Clinical Trials.” XVI World Congress of the International Society for Heart Research, Rhodes, Greece, May 28, 1998.

“Platelet GP IIb/IIIa Blockade and Coronary Stenting: Is There an Interaction?” Second International Preceptorship in Interventional Cardiology, The Christ Hospital, Cincinnati, Ohio, June 4, 1998.

“CACHET: The Interface of GP IIb/IIIa and Direct Thrombin Inhibition” Second International Preceptorship in Interventional Cardiology, The Christ Hospital, Cincinnati, Ohio, June 4, 1998.

“GP IIb/IIIa Blockers During Intervention in Acute Coronary Syndromes.” Current Medical and Interventional Therapy in Acute Coronary Syndromes, Mount Sinai School of Medicine, New York, New York, June 5, 1998.

“Case Management of Acute Myocardial Infarction.” Cleveland Clinic Foundation 10th Annual Intensive Review of Internal Medicine, Cleveland, Ohio, June 12, 1998.

“Overview of Pharmacology and Clinical Use of GP IIb/IIIa Blocking Agents in Coronary Angioplasty.” Recent Advances in Pharmacologic Antithrombotic and Thrombolytic Therapy, Working Group on Thrombosis and Platelets of the Portuguese Society of Cardiology, Portimao-Algarve, Portugal, June 20, 1998.

“Adjunctive Therapy During Coronary Intervention: Clinical Trials with IIb/IIIa Receptor Antagonists” and “Novel Therapeutic Targets in Unstable Angina: The Potential of IIb/IIIa Receptor Antagonists.” The Therapeutic Potential of Platelet IIb/IIIa Receptor Antagonists in Unstable Coronary Disease, Edinburgh International Conference Centre, Edinburgh, Scotland, July 10, 1998.

“Acute Myocardial Infarction and Its Complications” and “Arrhythmias: Management.” American College of Chest Physicians Critical Care Board Review - 1998, Washington, D.C., September 8, 1998.

“Periprocedural Myocardial Infarction: Real or Myth?” International Preceptorship in Interventional Cardiology, Cleveland Clinic Foundation, Cleveland, OH, September 24, 1998.

“Treatment of Unstable Angina with IIb/IIIa Inhibitors as Sole Therapy - Are Invasive Procedures Necessary?” Transcatheter Cardiovascular Therapeutics X, Washington, D.C., October 8, 1998.

“Role of IIb/IIIa Inhibitors During PTCA and Stenting in Patients with Stable Angina - Do the Trials Support their Routine Use?” Transcatheter Cardiovascular Therapeutics X, Washington, D.C., October 8, 1998.

“GP IIb/IIIa Inhibitors Administered at the Time of PCI for Patients with Acute Coronary Syndromes.” Evolving Treatment Strategies in Acute Coronary Syndromes: Issues and Insights for Interventional Cardiology. Transcatheter Cardiovascular Therapeutics X, Washington, D.C., October 8, 1998.

“EPISTENT: Abciximab Therapy with Balloon PTCA and Stents - Six Month Clinical Outcomes.” Transcatheter Cardiovascular Therapeutics X, Washington, D.C., October 8, 1998.

“Reperfusion Techniques in Acute Myocardial Infarction: Antithrombotic Adjuvant Therapies.” XXV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 21, 1998.

“Stents or IIB/IIIa Inhibitors in PTCA?” XXV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 21, 1998.

“Perspectives on the Treatment of Coronary Disease in 1998: Antithrombotic Therapy.” XXV Argentine Congress of Cardiology, Buenos Aires, Argentina, October 21, 1998.

“The EPISTENT Trial.” ReoPro/Retevase Investigators Meeting, Satellite Symposium of the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 6, 1998.

“Use of GP IIB-IIIa Inhibitors in the Management of Acute Coronary Syndromes: A Program for Cardiology Fellows. Considerations for the Interventional Cardiologist.” Satellite Symposium of the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 6, 1998.

“Intervent ‘99: Elective Stenting - How Does EPISTENT Affect Decision Making?” Satellite Symposium of the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 7, 1998.

“Long Term Results of the EPISTENT Trial.” American College of Cardiology Extended Learning Series (ACCEL). Recorded November 10, 1998.

“Abciximab and Eptifibatide in the Management of Acute Myocardial Infarction.” American College of Cardiology Extended Learning Series (ACCEL). Recorded November 10, 1998.

“Abciximab and Eptifibatide in the Management of Acute Myocardial Infarction.” Plenary Session of the 71st Scientific Sessions of the American Heart Association, Dallas, TX, November 11, 1998.

“Case Management of Acute Myocardial Infarction. 1st International Symposium Intensive Review of Internal Medicine” Association of Internal Medicine in Mexico and the Cleveland Clinic Foundation, Monterey, Mexico, November 17, 1998.

“Empiric Use of GP IIB/IIIa Antagonists in Acute Coronary Syndromes.” The Next Revolution in Clinical Cardiology: Advances in Antiplatelet Therapy - Interactive CME Satellite Videoconference. The Health Channel and Medical Broadcasting Company. November 30, 1998.

1999

“Enzyme Leaks and Gushes.” Coronary Stenting: Pitfalls Along the Road, Canadian Association of Interventional Cardiology, Internet Cybersession, February 2, 1999.

“Overview of Platelet Glycoprotein IIB/IIIa Receptor Blockade in Coronary Artery Disease.” 22nd Annual Cardiovascular Symposium, North Ridge Heart Institute, Fort Lauderdale, Florida, February 7, 1999.

“Update on the Management of Acute Coronary Syndromes.” Cardiology Update, Hearts and Arts III, Providence Heart Institute at the Detroit Institute of Arts, February 13, 1999.

“Management of Acute Coronary Syndromes: State of the Art.” Keynote Address, Centocor, Inc Annual Sales Meeting, Dana Point, California, March 3, 1999.

“State of the Art Lecture: Hot Unstable Angina.” Problem Solving in Interventional Cardiology: The CLINICS’ Approach, Satellite Symposium to the 48th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 5, 1999.

“What’s New in Antithrombotic Treatment of CAD 1998/1999.” Risk Factor Management Update, Satellite Symposium to the 48th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 6, 1999.

“Adjuncts - State of the Art: GP IIb/IIIa Inhibitors.” Myocardial Reperfusion XII: Concepts and Controversies, Satellite Symposium to the 48th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 6, 1999.

“EPISTENT 1-Year Mortality.” The Future of GP IIb/IIIa Inhibition: Combining Strategies for Optimal Outcomes, Satellite Symposium to the 48th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 6, 1999.

“Solving Clinical Challenges with Platelet Glycoprotein IIb/IIIa Blockade: Bleeding, Thrombocytopenia, Surgery, and Retreatment.” 2b/3a in Acute Coronary Syndromes: An Evidence-Based Approach, Satellite Symposium to the 48th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, March 6, 1999.

“IIb/IIIa Blockade in Combination with PCI and Stents - A Study Overview with Special Emphasis on EPISTENT.” Annual Swedish Cardiovascular Meeting, Malmo, Sweden, April 15, 1999.

“Angioplasty and Revascularization for Acute Coronary Syndromes.” Cardiology and Emergency Medicine: Collaborative Management of Acute Coronary Syndromes. Interactive CME Satellite Videoconference, Postgraduate Institute of Medicine, Raleigh, North Carolina, May 7, 1999.

“Debate: GP IIb/IIIa Molecules to Be Used in the CCU and the Cath Lab.” Cardiovascular Day, University of Montreal and University of Toronto, Toronto, Canada, May 13, 1999.

“Injury in the Diabetic Artery.” Second Restenosis Cybersummit, Internet Cybersession, May 14, 1999.

“Update on Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease.” Keynote Lecture, Taiwan Society of Cardiology 29th Annual Convention and Scientific Session, Taipei, Taiwan, May 16, 1999.

“Case Management of Acute Myocardial Infarction.” Cleveland Clinic Foundation 11th Annual Intensive Review of Internal Medicine, Cleveland, Ohio, June 11, 1999.

“GP IIb/IIIa in Combination With Stents.” International Workshop on The Era of GP IIb/IIIa Antagonists, Italian Working Group on Atherosclerosis, Thrombosis, and Vascular Biology, Como, Italy, June 17, 1999.

“Abciximab Trials in Coronary Stenting.” International Symposium IIb/IIIa Inhibitors in Ischemic Heart Disease, Madrid, Spain, June 18, 1999.

“Platelet GP IIb/IIIa Blockers During Coronary Intervention and Stenting.” Plenary Session: Restenosis - Strategies for Prevention and Treatment. 3rd International Meeting On Interventional Cardiology, Jerusalem, Israel, June 30, 1999.

“GP IIb/IIIa Blockade During PTCA and Atherectomy in Patients with Unstable Angina and Non-Q Wave MI - EPIC, EPILOG, CAPTURE, RESTORE, and IMPACT II” and “GP IIb/IIIa Blockade During Stenting - Lessons from EPISTENT and Bail-Out Stent Use in EPIC, EPILOG, and CAPTURE.” Acute Ischemic Syndromes: Pharmacologic & Mechanical Approaches. The Cardiovascular Training and Education Center at the Washington Hospital Center, Washington, D.C., July 7, 1999.

“EPISTENT - Is Abciximab Plus the Stent an Ideal Therapy?” The Brazilian Hemodynamic and Interventional Cardiology Convention, Curitiba, Brazil, July 15, 1999.

“Lesions with Thrombosis: Block Glycoprotein IIb/IIIa?” and “The Revolution of the Glycoprotein IIb/IIIa Inhibitors.” The Brazilian Hemodynamic and Interventional Cardiology Convention, Curitiba, Brazil, July 16, 1999.

Visiting Professorship, St. Luke's Episcopal Hospital and the Texas Heart Institute.

“Glycoprotein IIb/IIIa Inhibition and Optimal Reperfusion During Acute Myocardial Infarction,” Cardiology Basic Science Conference. “Current Issues in Glycoprotein IIb/IIIa Inhibition and Stenting: Mortality, Restenosis, and Practical Considerations,” Cardiology Grand Rounds, Houston, Texas, July 30, 1999.

“Stents and GP IIb/IIIa Inhibitors - The Latest.” Teleconference to 3rd Epworth Interventional Symposium, Victorian Heart Centre, Epworth Hospital, Richmond, Australia, September 9, 1999.

“Featured Lecture: Novel Aspects of IIb/IIIa Inhibitor Effects During Percutaneous Coronary Intervention - Beyond the Basics of EPIC, EPILOG, EPISTENT, ERASER, RAPPORT, IMPACT-II, and RESTORE.” Transcatheter Cardiovascular Therapeutics XI, Washington, D.C., September 22, 1999.

“EPISTENT: Reducing Mortality, Revealing Economic Benefit.” Transcatheter Cardiovascular Therapeutics XI, Washington, D.C., September 22, 1999.

“Are the Benefits of Adjunctive IIb/IIIa Inhibitors During Coronary Intervention Generalizable to Women?” Transcatheter Cardiovascular Therapeutics XI, Washington, D.C., September 23, 1999.

“Face the Facts: Abciximab is ‘King of the Cath Lab’” Transcatheter Cardiovascular Therapeutics XI, Washington, D.C., September 23, 1999.

“Cost-Effectiveness of Parenteral I Ib/IIIa Inhibitor Use in Acute Coronary Syndromes.”
Transcatheter Cardiovascular Therapeutics XI, Washington, D.C., September 24, 1999.

“Update on Abciximab During Percutaneous Coronary Intervention.” JEPPORT Trial
Symposium, Osaka, Tokyo, and Kokura, Japan, October 1-4, 1999.

“Antiplatelet Strategies for Acute Coronary Syndromes and Percutaneous Revascularization.”
The 4th International Symposium on Interventional Cardiology and Live Demonstration Course,
Dalian, China, October 8, 1999.

“Abciximab in Stenting.” XXth Congress of the Italian Society of Interventional Cardiology,
Naples, Italy, October 21, 1999.

“Coronary Interventions into the Next Millenium.” XXth Congress of the Italian Society of
Interventional Cardiology, Naples, Italy, October 22, 1999.

“Reperfusion Strategies in Perspective.” XXth Congress of the Italian Society of Interventional
Cardiology, Naples, Italy, October 23, 1999.

“GP I Ib/IIIa for Percutaneous Coronary Intervention: State of the Art in 2000.” Intervent 2000,
Satellite Symposium of the 72nd Scientific Sessions of the American Heart Association, Atlanta,
Georgia, November 6, 1999.

“EPISTENT 1-Year Outcome: Mortality, Diabetes, and Health Economics.” The I Ib/IIIa
Evolution: Stepping Up to a New Era, Satellite Symposium of the 72nd Scientific Sessions of the
American Heart Association, Atlanta, Georgia, November 6, 1999.

“Antiplatelet Agents and the Cardiac Surgical Patient.” Columbia/HCA Healthcare Corporation
CME Videoconference, Nashville, Tennessee, November 12, 1999.

“New Approaches in Pharmacologic Reperfusion in Acute MI.” Cardiovascular Preceptorship
Program, Cleveland Clinic Foundation, Cleveland, Ohio, December 6, 1999.

“Update on the Management of Unstable Angina and Non-ST Segment Elevation MI.” Medical
Resident Conference, Cleveland Clinic Foundation, Cleveland, Ohio, December 7, 1999.

“Glycoprotein I Ib/IIIa Receptor Blockade and Elective Stenting.” 13th Scientific Meeting of the
Japanese Coronary Association, Tokyo, Japan, December 10, 1999.

“What is the Role of Glycoprotein I Ib/IIIa Antagonists in Acute Myocardial Infarction?” 13th
Scientific Meeting of the Japanese Coronary Association, Tokyo, Japan, December 11, 1999.

“Update on the Management of Acute Myocardial Infarction.” Medical Resident Conference,
Cleveland Clinic Foundation, Cleveland, Ohio, December 15, 1999.

2000

“The EPISTENT Trial.” Cardiovascular Global Medical Conference 2000, Eli Lilly and Co,
Indianapolis, Indiana, March 10, 2000.

“Glycoprotein IIb/IIIa Antagonists in Acute Myocardial Infarction.” Cardiovascular Global Medical Conference 2000, Eli Lilly and Co, Indianapolis, Indiana, March 10, 2000.

“EPISTENT: 1-Year Mortality and Cost Effectiveness.” Combination Strategies 2000, Achieving Optimal Outcomes in Acute Coronary Syndromes, Satellite Symposium to the 49th Annual Scientific Session of the American College of Cardiology, Anaheim, California, March 11, 2000.

“Aggressive Versus Conservative Management of Acute Coronary Syndromes.” Association of Black Cardiologists 13th Annual Scientific Sessions, Satellite Symposium to the 49th Annual Scientific Session of the American College of Cardiology, Anaheim, California, March 11, 2000.

“Rationale For and Issues Surrounding the Use of GP IIb-IIIa Inhibitors in Combination with Low Molecular Weight Heparin in the ACS and PCI Setting.” New Concepts on the Use of GP IIb-IIIa Inhibitors, Satellite Symposium to the 49th Annual Scientific Session of the American College of Cardiology, Anaheim, California, March 11, 2000.

“GUSTO IV: Expanding Therapeutic Options in ACS (Unstable Angina, Non-Q-Wave MI, and Q-Wave MI).” Dawning of a New Era in Cardiovascular Medicine: Applying Evidence-Based Medicine to Real Life Practice, Satellite Symposium to the 49th Annual Scientific Session of the American College of Cardiology, Anaheim, California, March 11, 2000.

“First Clinical Investigation of a Tissue Factor Inhibitor Administered During Percutaneous Coronary Revascularization: A Randomized, Double-Blinded, Dose-Escalation Trial Assessing Safety and Efficacy of FFR-rFVIIa (ASIS) in PTCA. Late Breaking Clinical Trials in Interventional Cardiology, 49th Annual Scientific Session of the American College of Cardiology, Anaheim, California, March 12, 2000.

“GP IIb-IIIa Inhibitors for Unstable Angina.” New Adjunctive Therapies, Symposium of the 49th Annual Scientific Session of the American College of Cardiology, Anaheim, California, March 13, 2000.

“Implications of the EPILOG and EPISTENT Studies: Applying these Results in Daily Practice.” Texas Update in Cardiovascular Advancements, Austin, Texas, April 8, 2000.

“Cardiovascular Disease and American Academic Medicine: Promise and Crisis.” 12th National Managed Health Care Congress, Atlanta, Georgia, April 16, 2000.

“EPISTENT: Relevance to Diabetics, Economic Impact.” International Intensive Interventional Cardiology at the Cleveland Clinic Foundation, Cleveland, Ohio, April 17, 2000.

“State of the Art of GP IIb/IIIa Blockers in Coronary Intervention.” Angioplasty Summit 2000, The 5th International Live Demonstration and Update on Coronary Intervention in Seoul, Asian Medical Center, Seoul, Korea, April 29, 2000.

“New Antiplatelet Therapy: Practical Aspects.” Angioplasty Summit 2000, The 5th International Live Demonstration and Update on Coronary Intervention in Seoul, Asian Medical Center, Seoul, Korea, April 29, 2000.

“Safe Use of GP IIb/IIIa Inhibitors in Clinical Practice.” GP IIb/IIIa Blockade in Clinical Practice, Satellite Symposium to the Society of Cardiac Angiography and Interventions Annual Meeting, Charleston, South Carolina, May 4, 2000.

“New Pharmacologic Therapies for Acute Myocardial Infarction.” Cleveland Clinic Symposium, VI Congress of the Latin American Society of Interventional Cardiology, Caracas, Venezuela, July, 28, 2000.

“Antiplatelet Agents.” American College of Cardiology and Society for Cardiac Angiography and Interventions Board Review Program in Interventional Cardiology, San Francisco, CA, August 17, 2000.

“Mortality and Economic Benefits of Abciximab in Coronary Stenting.” New Standards of Care in Acute Coronary Syndromes, Explanation and Evidence, Satellite Symposium of the XXII Congress of the European Society of Cardiology, Amsterdam, The Netherlands, August 26, 2000.

“Controversies in the Treatment of Acute Coronary Syndromes as We Reach the New Millennium.” 5th International Congress of Cardiology, Salvador, Brazil, September 14, 2000.

“Antithrombotic Treatment: What is New and Hot and Why?” 5th International Congress of Cardiology, Salvador, Brazil, September 15, 2000.

“Use of Glycoprotein IIb/IIIa Antagonists During Percutaneous Coronary Revascularization.” 5th International Congress of Cardiology, Salvador, Brazil, September 14, 2000.

“Anticoagulant Therapies - Antiplatelets and Antithrombins.” An Intensive Review of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, September 25, 2000.

“Antiplatelet Agents.” American College of Cardiology and Society for Cardiac Angiography and Interventions Board Review Program in Interventional Cardiology, San Francisco, CA, August 17, 2000.

“Abciximab in Unstable Angina and Non-Q-Wave MI - The GUSTO IV ACS Trial.” Transcatheter Cardiovascular Therapeutics 2000, Washington, D.C., October 18, 2000.

“Will Bivalirudin Replace Heparin in the Cath Lab? Results of the CACHET Study.” Transcatheter Cardiovascular Therapeutics 2000, Washington, D.C., October 18, 2000.

“Combination therapy with Reduced-Dose Fibrinolytic and Platelet GP IIb/IIIa Receptor Inhibitors - SPEEDing into GUSTO IV.” Combination Strategies in Interventional Cardiology - Solutions from the Coronary Vasculature to the Periphery. Satellite Symposium of Transcatheter Cardiovascular Therapeutics 2000, Washington, D.C., October 18, 2000.

“More Lessons from EPISTENT.” GP IIb/IIIa Inhibitors in Interventional Cardiology: The Winning Edge, Satellite Symposium of Transcatheter Cardiovascular Therapeutics 2000, Washington, D.C., October 19, 2000.

“Unfractionated Heparin, LMW Heparins, and Direct Antithrombins: Mechanisms of Action, Relative Advantages and Side Effects, and Monitoring Issues.” Transcatheter Cardiovascular Therapeutics 2000, Washington, D.C., October 20, 2000.

“Using LMW Heparins in PCI With Eptifibatide (CRUISE).” Transcatheter Cardiovascular Therapeutics 2000, Washington, D.C., October 20, 2000.

“GP IIb/IIIa Inhibitors in Interventional Cardiology: Are There Differences in Outcomes with Different Compounds. A Look at EPISTENT (abciximab), ESPRIT (eptifibatide), TARGET (tirofiban) Trials.” The Medical and Interventional Therapies for Unstable Angina and Non-ST Elevation Myocardial Infarction, Charity University Hospital, Humboldt University, Berlin, Germany, November 2, 2000.

“State of the Art of GP IIb/IIIa Inhibitors in Interventional Cardiology.” Deutsches Herzzentrum, Munich, Germany, November 3, 2000.

“The Role of GP II/IIIa Receptor Antagonists in Unstable Angina.” Acute Coronary Syndromes, Bad Krozingen, Germany, November 4, 2000.

“Pharmacologic Strategies for Prevention and Treatment of Restenosis.” Microembolization, Satellite Symposium of the 73rd Scientific Sessions of the American Heart Association, New Orleans, Louisiana, November 11, 2000.

“Restenosis - The Rx Bullet is Still Alive.” Intervent 2001, Satellite Symposium of the 73rd Scientific Sessions of the American Heart Association, New Orleans, Louisiana, November 11, 2000.

“Stent Scrutiny.” Combination Strategies, Satellite Symposium of the 73rd Scientific Sessions of the American Heart Association, New Orleans, Louisiana, November 12, 2000.

2001

“The CACHET and REPLACE Trials.” Medicines Company Sales Training and Launch Meeting, Phoenix, Arizona, January 6, 2001.

Visiting Professorship, University of Pennsylvania. “Update on GP IIb/IIIa Antagonists in Coronary Intervention and Unstable Angina.” Division of Cardiovascular Medicine, Philadelphia, Pennsylvania, January 10, 2001.

“Clinical Update on the Status of GP IIb/IIIa Inhibitors.” Acute Coronary Syndromes Symposium, Myocardial Infarction Club, Antalya, Turkey, January 20, 2001.

“New Perspectives on Glycoprotein IIb/IIIa Inhibition.” Preceptorship for Advanced Cardiovascular Education, Cleveland Clinic Foundation, Cleveland, Ohio, February 27, 2001.

“Evidence for Facilitated Percutaneous Transluminal Coronary Angioplasty.” Eli Lilly Global Medical Conference, Indianapolis, Indiana, March 16, 2001.

“Clarifying Confusing and Conflicting GP IIb/IIIa Trial Results in ACS: The Case for Abciximab.” ACS and AMI: Pharmacological and Interventional Strategies. Satellite Session of the American College of Cardiology 50th Annual Scientific Session, Orlando, Florida, March 17, 2001.

“Applications of Direct Antithrombins - As a Replacement for IIb/IIIa Inhibitors?” ACS and AMI: Pharmacological and Interventional Strategies. Satellite Session of the American College of Cardiology 50th Annual Scientific Session, Orlando, Florida, March 17, 2001.

“New Adjuncts to PCI: Beyond Aspirin and Heparin. Bivalirudin - CACHET and REPLACE.” Myocardial Reperfusion. Satellite Session of the American College of Cardiology 50th Annual Scientific Session, Orlando, Florida, March 17, 2001.

“Adjunctive GP IIb/IIIa Inhibition in PCI: Is There Still A Controversy? EPISTENT, ESPRIT, TARGET.” Making a World of Difference in Acute Coronary Care, Satellite Session of the American College of Cardiology 50th Annual Scientific Session, Orlando, Florida, March 17, 2001.

“Exploring New Ways to Improve Post-PCI Outcomes: Bivalirudin as Monotherapy or in Combination with a Platelet Inhibitor.” The Evolution of Anticoagulation in Interventional Cardiology, Satellite Session of the American College of Cardiology 50th Annual Scientific Session, Orlando, Florida, March 17, 2001.

“Thrombocytopenia After Percutaneous Coronary Intervention.” Problem Solving in Interventional Cardiology. Invited Lecture at the American College of Cardiology 50th Annual Scientific Session, Orlando, Florida, March 18, 2001.

“GP IIb/IIIa Inhibitors Should Be Used in All Elective Coronary Interventions - Protagonist.” Controversies in Interventional Cardiology. Invited Lecture at the American College of Cardiology 50th Annual Scientific Session, Orlando, Florida, March 18, 2001.

“Antithrombotic Effect of Tissue Factor Inhibition by Active Site-Inhibited Seven (ASIS) During Coronary Intervention.” 6th Novo Nordisk Symposium on the Treatment of Bleeding and Thrombotic Disorders, Copenhagen, Denmark, May 4, 2001.

“Optimal Reperfusion Therapy for Acute Myocardial Infarction.” Sunnybrook and Women’s College Health Sciences Centre Cardiology Grand Rounds, Toronto, Canada, May 18, 2001.

“Antithrombotic Therapy in PCI: Contemporary Thinking.” Cleveland Clinic Foundation UK Preceptorship Program, Cleveland, Ohio, June 6, 2001.

“Case Management of Acute Myocardial Infarction.” Cleveland Clinic Foundation 13th Annual Intensive Review of Internal Medicine, Cleveland, Ohio, June 8, 2001.

“GUSTO V: Combining Therapies in Acute MI.” ACS Global CyberSummit 2001, Brigham and Women’s Hospital and Conceptis Technologies, June 21, 2001.

“Combining Half Dose Thrombolytic with Glycoprotein IIb/IIIa Inhibition.” 4th International Meeting on Interventional Cardiology: Frontiers in Interventional Cardiology, London, UK, June 25, 2001.

“Integrated View of Antithrombotic Therapy Trials of PCI.” 4th International Meeting on Interventional Cardiology: Frontiers in Interventional Cardiology, London, UK, June 25, 2001.

“Conservative versus Aggressive Managements of Acute Coronary Syndromes.” XVIIIth Congress of Dominican Cardiology, Santo Domingo, Dominican Republic, August 3, 2001.

“Unfractionated Heparin, Low Molecular Weight Heparins, and Direct Thrombin Inhibitors: Mechanisms of Actions, Relative Benefits, Side Effects, and Monitoring.” XVIIIth Congress of Dominican Cardiology, Santo Domingo, Dominican Republic, August 3, 2001.

“GUSTO V.” Hotline Session, Acute Myocardial Infarction, European Society of Cardiology XXIII Congress, Stockholm, Sweden, September 2, 2001.

“Optimal Pharmacologic Environment to Improve the Results of PCI in Acute MI.” Focus Session, Tips and Tricks for Primary PCI in Acute MI, Invited Lecture for the European Society of Cardiology XXIII Congress, Stockholm, Sweden, September 2, 2001.

“GUSTO V - Efficacy.” GUSTO V: Integrating the Results with Clinical Practice, Satellite Symposium of the European Society of Cardiology XXIII Congress, Stockholm, Sweden, September 3, 2001.

“Anticoagulant Therapies - Antiplatelets and Antithrombins.” 2nd Annual Intensive Review of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, August 11, 2001.

“The Case for Direct Thrombin Inhibitors During Percutaneous Coronary Intervention.” Scripps Clinic Coronary Interventions 2001, La Jolla, California, October 19, 2001.

“GP IIb/IIIa Inhibitions in the Cath Lab: Are We Saving Lives?” Scripps Clinic Coronary Interventions 2001, La Jolla, California, October 19, 2001.

“Adjunctive Antithrombotic Therapy to Thrombolysis.” Acute Coronary Syndromes: The Spectrum of Disease, Mount Sinai School of Medicine, New York, New York, October 29, 2001.

“Thrombolysis Prior to PTCA (Facilitated PCI).” Acute Coronary Syndromes: The Spectrum of Disease, Mount Sinai School of Medicine, New York, New York, October 29, 2001.

“Adjunctive Reperfusion Therapy for Acute Myocardial Infarction.” Cardiology Grand Rounds, University of California at San Francisco, San Francisco, California, December 5, 2001.

2002

“Antithrombotic Adjuncts to PCI.” Cardiology Grand Rounds, Baylor University School of Medicine, Houston, Texas, January 17, 2002.

"The World of Platelet Receptor Blockade." Lumen 2002 Vascular Interventions Symposium, Miami, Florida, February 7, 2002.

"Acute Coronary Syndromes." Third Annual Preceptorship for Advanced Cardiovascular Education, Cleveland Clinic Foundation, Cleveland, Ohio, February 25, 2002.

Visiting Professorship, William Beaumont Hospital, Division of Cardiology. "Direct Thrombin Inhibitors in Coronary Artery Disease," Cardiology Grand Rounds. "Optimal Reperfusion in Acute Myocardial Infarction," Cardiology Noon Conference, Royal Oak, Michigan, March 4, 2002.

"Bivalirudin - Ready to REPLACE Heparin?" Myocardial Reperfusion XV, Satellite Session of the American College of Cardiology 51st Annual Scientific Sessions, Atlanta, Georgia, March 16, 2002.

"Optimal Applications of Coronary Stents - Do All Patients Require IIB/IIIa's?" Invited Lecture at the American College of Cardiology 50th Annual Scientific Sessions, Atlanta, Georgia, March 19, 2002.

"Adjunctive Antithrombotic Therapy for Percutaneous Coronary Intervention: Linkage with Inflammation." Advances in Cardiovascular Medicine and Surgery, Texas Heart Institute, Houston, Texas, April 12, 2002.

"Glycoprotein IIB/IIIa Inhibitors - Contemporary Thinking." UK Physicians Preceptorship, Cleveland Clinic Foundation, Cleveland, Ohio, April 22, 2002.

"Genetic Variation in Platelet and Coagulation Proteins - Clinical Relevance." Genetics in Heart Disease: The Clinic's Perspective, Satellite Symposium at the AHA Asian Pacific Forum, Waikiki, Hawaii, April 24, 2002.

"GUSTO V - One Year Results." Hotline Session of the XIVth World Congress of Cardiology, Sydney, Australia, May 9, 2002.

"Current Status of Antithrombotic Adjuncts to Percutaneous Coronary Intervention." Hammersmith Hospital Cardiology Conference, London, England, June 13, 2002.

"Where Do We Stand With Facilitated PCI for ST Elevation MI: Can Pre-PCI Agents Improve Outcome?" Advanced Cardiovascular Interventions, Hilton Head, SC, June 20, 2002.

"Early vs Late Intervention in Acute Coronary Syndromes." Live Video Conference (broadcast from Cleveland Clinic) for V International Cardiology Symposium, Hospital Sao Lucas Da Pucrs, Porto Alegre, Brazil, June 27, 2002.

"Evolution of Acute MI Reperfusion Therapy." Coronary Therapeutics 2002, Oak Brook, IL, September 20, 2002.

"Unstable Ischemic Syndromes and Anticoagulant Therapies." 3rd Annual Intensive Review of Cardiology, Cleveland Clinic Foundation, Cleveland, OH, September 22, 2002.

“GP IIb/IIIa Inhibitors in Diabetics - Agent Specific? ACS or PCI? Mortality or Restenosis Reduction?” Transcatheter Cardiovascular Therapeutics 2002, Washington, D.C., September 25, 2002.

“Current Status of Antithrombotics and Antiplatelets in PCI.” GP IIb/IIIa Inhibitors in PCI - a Record of Success. Satellite Session of Transcatheter Cardiovascular Therapeutics 2002, Washington, D.C., September 25, 2002.

“The Case for Bivalirudin Replacing Unfractionated Heparin in PCI - Final REPLACE-1 Data and REPLACE-2 Update.” Transcatheter Cardiovascular Therapeutics 2002, Washington, D.C., September 26, 2002.

“Bivalirudin vs UFH in Patients with Unstable Angina Undergoing an Invasive Strategy: Insights from CACHET and REPLACE 1” Transcatheter Cardiovascular Therapeutics 2002, Washington, D.C., September 27, 2002.

“Coronary Revascularization and Diabetes Mellitus.” The 2nd Annual Diabetes Summit: Linking Science to Medicine. Satellite Symposium of the American Heart Association Scientific Sessions 2002, Chicago, IL, November 16, 2002.

“Direct Antithrombins: What, When, and Where for Non-ST Elevation MI.” Landmarks: Examining the Foundation for IIb/IIIas in PCI. Satellite Symposium of the American Heart Association Scientific Sessions 2002, Chicago, IL, November 16, 2002.

“REPLACE-2 Trial.” Late Breaking Clinical Trials Session - Interventional Cardiology 2002: Bench to Bedside and Beyond. American Heart Association Scientific Sessions 2002, Chicago, IL, November 17, 2002.

“Best of Scientific Sessions 2002 - REPLACE 2 Trial.” Educational program of the American Heart Association Scientific Sessions 2002, Chicago, IL, November 17, 2002.

“REPLACE-2 Trial.” Days In Review From Chicago, theheart.org, webcast of the American Heart Association Scientific Sessions 2002, Chicago, IL, November 17, 2002.

“GUSTO V. Where Are We After 1 Year.” Keeping Treatment Options Open in Acute Myocardial Infarction. Satellite Symposium of the American Heart Association Scientific Sessions 2002, Chicago, IL, November 17, 2002.

“REPLACE-2 Trial.” American College of Cardiology audio journal (ACCEL) interview, American Heart Association Scientific Sessions 2002, Chicago, IL, November 1, 2002.

2003

Visiting Professorship, University of North Carolina. “Thrombin Inhibitors in PCI.” Chapel Hill, NC, January 8, 2003.

“Is There a Role for Adjunctive Pharmacologic Therapy in the Era of Drug Eluting Stents?” 15th Annual International Symposium on Endovascular Therapy, Miami, FL, January 19, 2003.

“Update: Latest REPLACE 2 Data.” 15th Annual International Symposium on Endovascular Therapy, Miami, FL, January 19, 2003.

“GP IIb/IIIa - When and What Should We Use in 2003.” Cardiovascular Revascularization Therapy 2003, Washington, D.C., January 28, 2003.

“REPLACE II.” Cardiovascular Revascularization Therapy 2003, Washington, D.C., January 28, 2003.

“Clinical Implications of New Trials.” LUMEN Vascular Interventions Symposium, Miami, FL, February 7, 2003.

“REPLACE-2.” Meeting of the Indian Society of Interventional Cardiology, Miami, FL, February 7, 2003.

“ACS: New Concepts and New Therapies.” 1st International Symposium on Coronary Heart Disease - Albert Einstein Hospital and Cleveland Clinic Foundation, Sao Paulo, Brazil, February 21, 2003.

“Current Approaches to Reperfusion Therapy in Acute Ischemic Syndromes.” 1st International Symposium on Coronary Heart Disease - Albert Einstein Hospital and Cleveland Clinic Foundation, Sao Paulo, Brazil, February 22, 2003.

“Update on Antithrombotic Therapies During Percutaneous Coronary Revascularization.” 1st International Symposium on Coronary Heart Disease - Albert Einstein Hospital and Cleveland Clinic Foundation, Sao Paulo, Brazil, February 22, 2003.

“REPLACE All Other Rx.” Myocardial Reperfusion XVI: Concepts and Controversies, Satellite Session of the American College of Cardiology 52nd Annual Scientific Sessions, Chicago, IL, March 29, 2003.

“Update on REPLACE-2 Results.” REPLACE-2 Symposium: Economics of Care and Clinical Subsets - the Inside Story, Satellite Session of the American College of Cardiology 52nd Annual Scientific Sessions, Chicago, IL, March 29, 2003.

“Complementary Therapies in the Cath Lab: Drugs and Devices.” Day in Review, Chicago ‘03. theheart.org (CME accredited web broadcast), Chicago, IL, April 1, 2003.

“A New Standard of Anticoagulation Therapy in PCI.” CME accredited satellite and web broadcast, Cleveland, OH, April 9, 2003.

“Interventional Pharmacology: Bivalirudin in ACS and PCI.” 9th Annual Interventional Fellows Course, San Jose, California, April 11, 2003.

“Life After REPLACE-2. How Should the Results Impact Clinical Practice In and Out of the Cath Lab.” 9th Annual Interventional Fellows Course, San Jose, California, April 11, 2003.

“Anti-Platelets and Anti-Thrombotics in ACS and PCI.” 1st Annual New Jersey Cardiovascular Symposium: An Update on Acute Coronary Syndromes, Newark, New Jersey, May 2, 2003.

“Case Management of Acute Myocardial Infarction.” Cleveland Clinic Foundation 15th Annual Review of Internal Medicine, Cleveland, Ohio, June 2, 2003.

“Contemporary Anticoagulation Therapies in ACS and PCI.” Cleveland Clinic Foundation Interventional Preceptorship, Cleveland, Ohio, June 4, 2003.

“Message from Recent Trials: CREDO and REPLACE Trials.” Live Symposium of Complex Coronary and Vascular Cases VI, Mt. Sinai Hospital, New York, New York, June 12, 2003.

“Current Management Strategies for ACS.” Live Video Conference (broadcast from Cleveland Clinic) for 2003 International Cardiology Meeting in Porto Alegre Brazil, June 26, 2003.

“PCI Adjuvant Antithrombotic Therapy.” Interventional Cardiology Review Course, Brazilian Society of Interventional Cardiology, San Paolo, Brazil, July 23, 2003.

“Low Molecular Weight Heparin Reigns Supreme?” IX Congress of SOLACI and XXV Congress of SBHCI, Sao Paolo, Brazil, July 23, 2003.

“Direct Thrombin Inhibitors and/or GP IIb/IIIa Blockers in PCI.” IX Congress of SOLACI and XXV Congress of SBHCI, Sao Paolo, Brazil, July 24, 2003.

“REPLACE-2 6 Month Results.” Plenary Sessions - Late Breaking Clinical Trials, Transcatheter Cardiovascular Therapeutics 2003, Washington, D.C., September 15, 2003.

“GP IIb/IIIa Inhibitors: Has Their Role Changed after REPLACE-2?” Transcatheter Cardiovascular Therapeutics 2003, Washington, D.C., September 16, 2003.

“Bivalirudin in PCI: Have Heparin and IIb/IIIa Inhibitors Been REPLACED?” Transcatheter Cardiovascular Therapeutics 2003, Washington, D.C., September 16, 2003.

“REPLACE-2: A Prospective, Randomized Trial of Bivalirudin vs Heparin and IIb/IIIa in PCI.” Top Interventional Trials of the Last Year, Transcatheter Cardiovascular Therapeutics 2003, Washington, D.C., September 17, 2003.

“Fibrinolytic and Anticoagulant Strategies for Unstable Angina and Acute Myocardial Infarction.” 4th Annual Intensive Review of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio, September 21, 2003.

“Glycoprotein IIb/IIIa Blockade in PCI - Contemporary Thinking.” International Physicians Preceptorship, Cleveland Clinic Foundation, Cleveland, Ohio, October 8, 2003.

“Vulnerable Plaque - Where Do We Stand in 2003?” XIII National Congress of the Mexican Society of Interventional Cardiology, Monterrey, Mexico, November 19, 2003.

“Modern Use of Glycoprotein IIb/IIIa Inhibitors.” XIII National Congress of the Mexican Society of Interventional Cardiology, Monterrey, Mexico, November 20, 2003.

“Results at 6-Months of REPLACE-2.” XIII National Congress of the Mexican Society of Interventional Cardiology, Monterrey, Mexico, November 20, 2003.

“Adjunctive Pharmacology in Acute MI Interventions.” 5th International Meeting on Interventional Cardiology: Frontiers in Interventional Cardiology, Tel Aviv, Israel, December 8, 2003.

“The Future of Adjunctive Pharmacology in Percutaneous Interventions.” 5th International Meeting on Interventional Cardiology: Frontiers in Interventional Cardiology, Tel Aviv, Israel, December 9, 2003.

2004

“Role for Adjunctive Pharmacotherapy in the Era of Drug Eluting Stents.” International Symposium on Endovascular Therapy, Miami, Florida, January 25, 2004.

“Contemporary Anticoagulation Regimens for PCI.” Aultman Health Foundation, Canton, OH, January 28, 2004.

“Adjunctive Pharmacotherapy for PCI.” Department of Cardiology Grand Rounds, Case Western Reserve University Hospitals, Cleveland, OH, February 18, 2004.

“Glycoprotein IIb/IIIa Inhibitors.” Cleveland Clinic Interventional Summit, Cleveland, Ohio, February 26, 2004.

“Antithrombin Therapy in Acute MI.” Myocardial Reperfusion XVII: Concepts and Controversies. Satellite Symposium of the American College of Cardiology 53rd Annual Scientific Sessions, New Orleans, Louisiana, March 6, 2004.

“Clopidogrel in Cardiovascular Disease.” The 9th International Live Demonstration Course - Angioplasty Summit 2004, Cardiovascular Research Foundation, Seoul, Korea, April 29, 2004.

“Contemporary Antithrombotic Therapy in PCI.” The 9th International Live Demonstration Course - Angioplasty Summit 2004, Cardiovascular Research Foundation, Seoul, Korea, April 29, 2004.

“REPLACE 2 and New Applications for Thrombin Inhibitors.” Cardiovascular Revascularization Therapy 2004, Washington, DC, May 6, 2004.

“Aspirin and Plavix Resistance.” Cardiovascular Revascularization Therapy 2004, Washington, DC, May 6, 2004.

“REPLACE-2 and Adjunctive Pharmacology During Percutaneous Coronary Intervention.” The Paris Course on Revascularization - EuroPCR, Paris, France, May 27, 2004.

“Use of Antithrombins.” Intervention 2004, A National Cardiovascular Symposium, Cleveland, Ohio, June 3, 2004.

“Optimal Antiplatelet-Antithrombin Therapy: The Case for Direct Thrombin Inhibitors.” 13th Interventional Cardiology Live Course, Institut de Cardiologie de Montreal, Montreal, Canada, June 9, 2004.

“Primary Angioplasty for Acute Myocardial Infarction.” Advances in Treatment of Coronary Artery Disease - A Comprehensive Review, New York Presbyterian Hospital, New York, New York, June 11, 2004.

“REPLACE-2 and Adjunctive Pharmacology During PCI.” Cardiology Grand Rounds, Newark Beth Israel Hospital, Newark, New Jersey, June 25, 2004.

“Contemporary Antithrombotic Strategies During Acute Ischemic Syndromes and PCI.” Monterrey Society of Cardiology, Monterrey, Mexico, July 29, 2004.

“Fibrinolytic and Anticoagulant Strategies for Unstable Angina and Acute MI.” An Intensive Review of Cardiology - 5th Annual, Cleveland Clinic Foundation, Cleveland, Ohio, September 24, 2004.

“Antithrombotic Strategies in Percutaneous Coronary Intervention.” Cardiology Grand Rounds, Yale-New Haven Hospital, New Haven, Connecticut, October 29, 2004.

“Contemporary Use of Bivalirudin.” Evidence Based Medicine for the Interventional Cardiologist, Satellite Symposium of the American Heart Association Scientific Sessions 2004, New Orleans, LA, November 6, 2004.

“Invasive Treatment of Acute Coronary Syndromes.” Mexican Society of Interventional Cardiology (SOCIME) Congress 2004, Mexico City, Mexico, November 18, 2004.

“GP IIb/IIIa Inhibitors and Bivalirudin in PCI.” Main Conference, Mexican Society of Interventional Cardiology (SOCIME) Congress 2004, Mexico City, Mexico, November 18, 2004.

“Aspirin and Plavix Resistance.” 6th International Meeting on Interventional Cardiology, Tel Aviv, Israel, December 6, 2004.

“Bivalirudin in Percutaneous Coronary Intervention: REPLACE-2 Study and U.S. Experience.” Antithrombotic Treatment in Coronary Interventions, Helsinki University Central Hospital, Helsinki, Finland, December 8, 2004.

2005

“Antithrombotic Therapy and Bivalirudin in PCI.” Arizona Heart Institute, Phoenix, Arizona, January 12, 2005.

“Contemporary Antithrombotic Therapy in PCI.” California Pacific Medical Center Grand Rounds, San Francisco, California, February 23, 2005.

“Antithrombotic Therapy in ACS and Angioplasty.” 2nd International Symposium on Coronary Artery Disease - Albert Einstein Hospital and Cleveland Clinic, Sao Paulo, Brazil, February 25, 2005.

“Aspirin and Clopidogrel Resistance: Differences in Platelet Function.” 2nd International Symposium on Coronary Artery Disease - Albert Einstein Hospital and Cleveland Clinic, Sao Paulo, Brazil, February 25, 2005.

“Antithrombotic Therapy in CAD.” Smith Barney Symposium, Cleveland Clinic Foundation, Cleveland, Ohio, February 28, 2005.

“Bivalirudin for Primary PCI.” Myocardial Reperfusion XVIII: Concepts and Controversies. Satellite Symposium of the American College of Cardiology 54th Annual Scientific Sessions, Orlando, Florida, March 5, 2005.

“Best Therapy for ACS.” Meet the Experts, American College of Cardiology 54th Annual Scientific Sessions, Orlando, Florida, March 8, 2005.

“Adjunctive Therapy for Percutaneous Coronary Intervention.” Brown Bag Lunch Panel, American College of Cardiology 54th Annual Scientific Sessions, Orlando, Florida, March 8, 2005.

“Engineering Applications in Cardiovascular Medicine.” Introduction to Chemical Engineering course, Carnegie Mellon University, Pittsburgh, Pennsylvania, April 11, 2005.

“Interventional Pharmacology: Bivalirudin in ACS and PCI.” 11th Annual Interventional Cardiology Fellows Course, Cardiovascular Research Foundation, Boston, Massachusetts, April 15, 2005.

“Direct Thrombin Inhibitor Update.” Cleveland Clinic Foundation Second Annual Interventional Summit, Cleveland, Ohio, April 22, 2005.

“Antithrombotic Therapy During PCI.” Cardiovascular Preceptorship Program, Cleveland Clinic Foundation, Cleveland, Ohio, April 22, 2005.

“Recent Advances in Interventional Cardiology.” 41st Annual Robert M. Jersaty, M.D. Cardiovascular Symposium, Saint Francis Hospital and Medical Center and the Hoffman Heart Institute of Connecticut, Hartford, Connecticut, April 27, 2005.

“All the Places to REPLACE: Bivalirudin as a Foundation Antithrombotic Agent in the Setting of PCI. Optimizing Outcomes, Safety, and Efficiency in the Catheterization Laboratory - Applying Landmark Evidence to Interventional Cardiology, Society of Cardiac Angiography and Intervention Annual Meeting, Ponte Vedra Beach, Florida, May 4, 2005.

“Contemporary Antithrombotic Therapy in PCI.” Mount Sinai Hospital Cardiology Grand Rounds, Miami, Florida, May 18, 2005.

“Optimal Antithrombotic Regimen for PCI.” Cardiovascular Preceptorship Program, Cleveland Clinic Foundation, Cleveland, Ohio, May 20, 2005.

“Case Management of Acute Myocardial Infarction.” Cleveland Clinic Foundation Board Review of Internal Medicine, Cleveland, Ohio, June 6, 2005.

“Contemporary Antithrombotic Therapy in PCI and ACS.” Mitsubishi Pharma Corporation
Scientific Advisory Board, Yokohama, Japan, June 21, 2005.

March 31, 2006

**APPEARS THIS WAY
ON ORIGINAL**